Stockwinners Market Radar for January 18, 2022 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:09 EST Rackspace Technology to acquire Just Analytics - Rackspace Technology (RXT) "announced that it has agreed to acquire Just Analytics, a leading provider of cloud-based data, analytics, and Artificial Intelligence services based in the Asia Pacific and Japan region. Additionally, this acquisition brings strong regional ties into the Microsoft Azure ecosystem with Just Analytics recently being awarded four regional Microsoft (MSFT) partner of the year awards."

18:05 EST Ero Copper reports two separate fatal incidents at its operations - Ero Copper Corp. reported that, in recent days, two separate and isolated incidents occurred at its operations resulting in fatal injuries being sustained by two employees. One incident occurred at the Company's MCSA Mining Complex, and the second incident occurred at its NX Gold Mine. No other personnel were injured. Following each incident, the Company voluntarily suspended each of its operations to allow for investigations to be conducted and for leadership to provide support for the employees' families and affected staff. Since the incident at the MCSA Mining Complex late last week, mining and milling operations have resumed. Since the incident at the NX Gold Mine yesterday evening, operations have been suspended as part of a site-wide safety stop initiative and are expected to resume within the next 24 hours. The company is actively assisting in the investigation of these incidents.

18:01 EST SoFi Technologies gets regulatory approval to become national bank - SoFi Technologies "announced that the Office of the Comptroller of the Currency and the Federal Reserve have approved its applications to become a Bank Holding Company through its proposed acquisition of Golden Pacific Bancorp, Inc., and operate its bank subsidiary as SoFi Bank, National Association. SoFi expects the acquisition to close in February, subject to completion or waiver of the remaining customary closing conditions."

17:57 EST Ellington Financial reports estimated book value per share $18.39 on December 31 - This estimate includes the effect of the previously announced monthly dividend of 15c per share of common stock, payable on January 25, 2022 to holders of record on December 30, 2021, with an ex-dividend date of December 29, 2021.

17:34 EST United Community Banks reports Q4 operating EPS 64c, consensus 64c - Reports Q4 revenue $175.4M, consensus $178.67M. CEO Lynn Harton stated, "We are very pleased by United's performance this quarter and in 2021. In the quarter, both loan and deposit growth were strong and noninterest income benefited from strong, but seasonally lower, mortgage production and a great SBA quarter. On the strategic front, we completed the acquisition of Aquesta Financial Holdings, Inc. and Aquesta Bank on October 1, boosting our Charlotte presence and adding the Wilmington, North Carolina market, both of which are growth markets that fit well with our footprint and culture. We also completed the operational conversion of Aquesta in mid-November, bringing the United brand to these great markets. We are proud that this outstanding team of bankers has joined us and we believe that they are a great fit for United. Finally, while not included in the quarterly results, on January 1 we completed the acquisition of Reliant Bancorp, expanding our Tennessee presence into the fast-growing Nashville MSA with a very high performance organization."

17:30 EST AstraZeneca's TOPAZ-1 trial of Imfinzi shows reduced risk of death in BTC - The company states: "Positive results from the TOPAZ-1 Phase III trial showed AstraZeneca's Imfinzi, in combination with standard-of-care chemotherapy, demonstrated a statistically significant and clinically meaningful improvement in overall survival and progression-free survival versus chemotherapy alone as a 1st-line treatment for patients with advanced biliary tract cancer, or BTC. These results will be presented on 21 January at the 2022 American Society of Clinical Oncology Gastrointestinal Cancers Symposium. Results also showed a 25% reduction in the risk of disease progression or death with Imfinzi plus chemotherapy. Median PFS was 7.2 months for the combination versus 5.7 for chemotherapy. Patients treated with Imfinzi plus chemotherapy achieved an objective response rate of 26.7% versus an ORR of 18.7% for patients treated with chemotherapy alone." Reference Link

17:19 EST Pinnacle Financial announces new $125M share repurchase plan - The firm announced that its Board of Directors has authorized a new share repurchase program for up to $125M of the company's common stock to commence upon expiration of its existing share repurchase program that is set to expire on March 31. The board authorized the repurchase program to remain in effect through March 31, 2023, unless the entire repurchase amount has been acquired before that date.

17:06 EST Fastenal raises quarterly dividend to 31c from 28c per share - To be paid in cash on March 2 to shareholders of record at the close of business on February 2.

17:02 EST Dirtt Environmental CEO Kevin O'Meara leaves, Todd Lillibridge named interim CEO - Dirtt Environmental announced the departure of Kevin O'Meara as the company's CEO and as a director. Todd Lillibridge, the Board Chair, has been appointed Interim CEO, and will serve until his replacement is named. The Board also named Michael Ford as Lead Independent Director for the period Lillibridge serves as CEO. The Board has retained an executive search firm to help it identify a permanent leader for the company. Lillibridge does not intend to be a candidate for the permanent role. Lillibridge has served on the DIRTT Board since 2017. He has over thirty years of executive experience in the healthcare real estate industry, having founded and built a multi-billion-dollar medical office building business.

16:47 EST Prosperity Bancshares authorizes stock repurchase program of up to 5% - Prosperity Bancshares authorized a stock repurchase program under which the company may repurchase up to 5%, or approximately 4.6 million shares, of its outstanding common stock over a one-year period expiring on January 18, 2023, at the discretion of management. Any repurchased shares will be held by the company as authorized but unissued shares. The company may suspend, modify or terminate the program at any time and for any reason, without prior notice.

16:35 EST Wendy's evaluating potential debt raise transaction - The Wendy's Company announced that it is evaluating, subject to market and other conditions, a potential debt raise transaction within its securitized debt facility. If the company proceeds with this transaction it could complete this as early as the end of the first quarter of 2022. If the transaction is completed, the company expects to use the net proceeds from the transaction in accordance with its capital allocation policy, including investments to support the growth of the Wendy's brand or the return of capital to shareholders through dividends and share repurchases. As a result of the timing of this potential transaction, the company has revised the dates for reporting its fourth quarter and full year 2021 results and hosting its 2022 investor day.

16:33 EST Valaris awarded two one-well contracts - Valaris announced that it has been awarded two one-well contracts with subsidiaries of Murphy Oil Corporation for semisubmersible VALARIS DPS-5. The first contract is in the U.S. Gulf of Mexico and is expected to commence in Q3 with a minimum duration of 30 days. This contract has a one-well option with an estimated duration of 90 days. The second contract, offshore Mexico, will commence in direct continuation of the first contract and has an estimated duration of 60 days.

16:31 EST Safehold announces expansion into Chicago market - Safehold announced its expansion into the Chicago market, offering its modern, customer-friendly Safehold ground lease to facilitate the recapitalization of 1000 South Clark, a Class A multifamily building in Downtown Chicago, IL. The transaction closed in December 2021. "We are excited to begin offering the Chicago MSA a better, more efficient way to capitalize its real estate," said Tim Doherty, Head of Investments. "The ground lease capital provided to our new customer, JDL Development, allowed them to acquire full ownership of the building while securing the lowest cost capital available in the market."

16:31 EST American Financial Group buys Verikai for $120M in cash - American Financial Group "announced the acquisition of Verikai, a machine learning and artificial intelligence company that utilizes a predictive risk tool for assessing insurance risk, effective December 2021. Verikai will continue to be led by its President and CEO, Jeff Chen. AFG paid approximately $120M in cash at closing."

16:23 EST One Gas sees capital investments $650M-$750 per year through 2026 - For the five years ending 2026, capital investments, including asset removal costs, are expected to be in the range of $650 million to $750 million per year, or approximately $3.5 billion for the five-year period, an increase of 19% from the previous five-year plan. The increase in capital supports estimated average rate base growth of 8% to 9% per year through 2026, an increase from the prior five-year forecast of 7% to 8%. While continuing to allocate more than 65% of total capital investments to system integrity and replacement projects, the Company anticipates strong growth, primarily in Texas and Oklahoma. Over the five-year period ending 2026, growth capital is estimated to be approximately $1.1 billion, an increase of 23% from the previous five-year plan. Net income is expected to increase by an average of 8% to 10% annually through 2026, up from 6% to 8%, with diluted earnings per share now at 6% to 8%, up from 5% to 7%. Operating costs over the five years are expected to increase on average approximately 4% per year. ONE Gas estimates total net financing needs for the period 2022 through 2026 of approximately $1.6 billion, of which approximately 25% is expected to be equity. The average annual dividend growth rate is expected to remain 6% to 8% through 2026, subject to board of directors' approval, with a target dividend payout ratio of 55% to 65% of net income.

16:22 EST B. Riley Financial to acquire FocalPoint Securities for up to $175M - B. Riley Financial announced it has agreed to acquire FocalPoint Securities, an independent investment bank based in Los Angeles, for total consideration of up to $175M. The transaction, which will create revenue synergies for both companies, comes as FocalPoint is experiencing significant momentum with $17B in closed transactions spanning a successful 20-year history. The combination is expected to more than quadruple B. Riley's pro forma M&A advisory business, while significantly enhancing its debt capital markets and financial restructuring capabilities.

16:17 EST One Gas increases quarterly dividend by 4c to 62c per share - One Gas increased the dividend for Q1 by 4c per share to 62c per share, resulting in an annualized dividend of $2.48 per share. The dividend is payable March 11 to shareholders of record at the close of business Feb. 25. The company expects an average annual dividend increase of 6% to 8% through 2026, with a target dividend payout ratio of 55% to 65% of net income, subject to its board of directors' approval.

16:14 EST PS Business Parks names Stephen Wilson interim CEO - PS Business Parks (PSB) announced the appointments of Stephen W. Wilson as interim President and Chief Executive Officer and Maria R. Hawthorne as interim Chief Operating Officer, effective January 17, 2022. Mr. Wilson has been a director of the Company since 2019 and served as Executive Vice President-Development at AvalonBay Communities, Inc. (AVB) prior to his retirement in 2019. Ms. Hawthorne has been a Company director since 2016 and previously served in various senior leadership positions at the Company, including as President and Chief Executive Officer, prior to her retirement in 2021. Dan "Mac" Chandler, III, the Company's President and Chief Executive Officer, is taking a temporary leave of absence for health reasons unrelated to the coronavirus pandemic, effective January 17, 2022. The Company further noted that, as previously announced, Adeel Khan has joined the Company as Executive Vice President, Chief Financial Officer and Corporate Secretary, effective January 10, 2022. Mr. Khan previously served as Chief Financial Officer of Rexford Industrial Realty, Inc. (REXR), from July 2013 through August 2020.

16:12 EST Wells Fargo names Derek Flowers chief risk officer - Wells Fargo announced today that Derek Flowers has been appointed the company's Chief Risk Officer, effective immediately. Flowers will lead all aspects of Wells Fargo's Independent Risk Management function, including compliance risk management. He will continue to serve as a member of the company's Operating Committee. "Derek is a proven leader with extensive experience managing risk. Over the last several years, he has played a critical role managing the buildout of the company's risk and control frameworks," said Charlie Scharf, Wells Fargo's CEO. "Building a risk and control foundation appropriate for Wells Fargo's size and complexity remains our top priority, and Derek's background and familiarity with the company - built on a 24-year career at Wells Fargo - make him the ideal candidate to succeed Mandy Norton following her retirement."

16:09 EST Kinnate announces FDA clearance of IND application for KIN-3248 - Kinnate Biopharma announced that the U.S Food and Drug Administration FDA has cleared the company's Investigational New Drug IND application for KIN-3248, a next-generation pan-FGFR inhibitor being developed for intrahepatic cholangiocarcinomaICCand urothelial carcinoma UC. "The IND clearance for KIN-3248 is another important validation of our Kinnate Discovery Engine and an exciting step forward in our mission to deliver new therapies to patients with difficult-to-treat, genomically-defined cancers," said Nima Farzan, Chief Executive Officer of Kinnate. "By targeting clinically relevant primary FGFR driver alterations and secondary resistance mutations, including FGFR2 and FGFR3 gatekeeper, molecular brake, and activation loop mutations, we believe that KIN-3248 is unique among FGFR inhibitors and has the potential to extend the clinical response of cancer patients with FGFR-altered tumors."

16:08 EST Qiagen launches QIAwave portfolio of environmentally friendly products - Qiagen announced its new QIAwave product line by launching three nucleic acid extraction kits that use fewer components and produce less waste than existing ones. They are the first of their type to use both recycled plastics and space-saving chemical concentrates. The QIAwave RNA Mini Kit, QIAwave DNA Blood & Tissue Kit and QIAwave Plasmid Miniprep Kit use up to 63% less plastic and up to 42% less cardboard than QIAGEN's most popular kits for extracting DNA, RNA and plasmid DNA from samples. That makes them a more sustainable alternative to existing products - a major step in reducing the environmental impact of QIAGEN's overall portfolio. "QIAwave products are designed in collaboration with our customers to tackle the persistent problem of laboratory waste faced by scientists all over the world," said Thomas Schweins, Senior Vice President, Head of Life Sciences. "These three kits are the first in a wave of continuous improvements and product evolutions that will reduce the environmental footprint of our products, while still delivering the same QIAGEN quality."

16:07 EST Ford sees $8.2B Q4 gain on equity investment in Rivian - Ford (F) outlined several large special items that it intends to report in early February as part of the company's fourth-quarter and full-year 2021 financial results. Special items are included in Ford's reported GAAP net income and earnings per share, but are excluded from its non-GAAP adjusted earnings before interest and taxes and adjusted EPS. On a preliminary basis, the special items are expected to include: A fourth-quarter gain of $8.2 billion on Ford's equity investment in Rivian (RIVN), following Rivian's Nov. 10 initial public offering of common stock and a mark-to-market revaluation of the holdings. Additionally, Ford will reclassify its ~$900 million first-quarter 2021 non-cash gain on the Rivian investment as a special item - a step Ford said in October it would take after Rivian's IPO. The reclassification means the gain from first-quarter 2021 will not be included in Ford's full-year adjusted EBIT or adjusted EPS. When Ford last provided full-year adjusted EBIT guidance with its third-quarter results on Oct. 27, the ~$900 million gain was included in the forecast range of $10.5 billion to $11.5 billion. Going forward, mark-to-market revaluations to account for changes in Rivian's stock price could result in related gains or losses each quarter reported as special items. Another special item is an annual revaluation of Ford's global pension and other post-retirement employee benefits - resulting in a non-cash, pre-tax accounting re-measurement gain of about $3.5 billion in the fourth quarter and about $3.9 billion for the full year. Overall, the remeasurement gain is mostly attributable to higher discount rates and asset returns. Other items include: Recording about $1.7 billion in costs associated with Ford repurchasing and redeeming more than $7.6 billion in high-cost debt in the fourth quarter, and; Reporting a $3.6 billion tax special item - a non-cash benefit - primarily resulting from changes in Ford's global tax structure and its effect on deferred tax assets.

16:06 EST Galapagos says MHRA licenses Jyseleca for treatment of ulcerative colitis - Galapagos announced that the Medicines and Healthcare products Regulatory Agency, MHRA, has granted a marketing authorization for Jyseleca, filgotinib 200mg tablets, as a new treatment for ulcerative colitis UC for Great Britain. The MHRA has licensed an additional indication for Jyseleca, an oral once-daily, JAK1 preferential inhibitor, for use in adult patients with moderately to severely active UC who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic agent. The submission was supported by data from the Phase 2b/3 SELECTION program, published in the Lancet1. The decision from the MHRA follows authorisation from the European Commission for use in the same patient population. Michele Manto, Chief Commercial Officer at Galapagos said: "At Galapagos we are committed to bringing new and innovative medicines to healthcare professionals who are treating patients with UC and today we are one step closer to offering a new treatment option to thousands of patients living in Great Britain with UC, a chronic and debilitating disease. Together with the EC decision, this decision represents an important milestone in our plans to make Jyseleca available to eligible adult patients with UC across Europe."

16:04 EST Rise Education receives Nasdaq non-compliance notice - Rise Education was notified by the Listing Qualifications department of Nasdaq on January 11 that the Staff had determined to delist the company's securities unless the company timely requested a hearing before a Nasdaq Hearings Panel. The Staff concluded that the company is a "public shell" as defined in Nasdaq Listing Rules the result of the company's sale of substantially all of its assets on December 30, 2021, as well as the company's failure to timely file its interim balance sheet and income statement for the period ended June 30, 2021 with the SEC. The company filed its interim balance sheet and income statement for the period ended June 30, 2021 with the SEC on January 11 and has therefore regained compliance with Nasdaq Listing Rule 5250(c)(2). The company requested a hearing before the Panel, which has stayed any further delisting action by Nasdaq at least pending the hearing. At the hearing, the company will present its plan to evidence compliance with all applicable Nasdaq listing criteria and request an extension of time to do so. To that end, the company is actively pursuing strategic business opportunities that include operating activities that will generate revenue.

16:03 EST Betterware de Mexico to acquire JAFRA's operations in Mexico and U.S. for $255M - Betterware de Mexico announced that it has signed a Definitive Agreement to acquire 100% of JAFRA's operations in Mexico and the United States from the Vorwerk Group based in Germany for a total cash consideration of $255M, equivalent to Ps. 5,355mm, on a debt-free, cash-free basis. The purchase price implies a valuation multiple of ~5.5x 2022E EBITDA prior to the identified cost synergies of $5M-$10M, and 4.8x 2022E EBITDA considering the mid-point of the synergies. The company expects to close the transaction in the first half of 2022, subject to antitrust and regulatory approval in Mexico. Betterware expects the acquisition to be highly accretive in the first year. The deal is expected to add approximately $0.341/share to EPS in 2022E and over $46M of EBITDA without considering any of the identified cost synergies, which represents an accretion of ~15% when considering Betterware's 3Q21 LTM EPS of $2.45, considering the mid-point of the synergies the EPS would be US$0.48 representing an accretion of ~20% and an EBITDA add of $54M. The acquisition is expected to be funded through a combination of $225M debt financing and US$30mm of existing cash on hand. Following the transaction, Betterware expects to continue to possess a strong balance sheet and a low leverage ratio of ~1.4x allowing the company to also invest in support of its growth and continue to pay its quarterly dividend of Ps. 9.38 per share. During 2Q21, Betterware initiated preliminary conversations with JAFRA which resulted in the signing of a non-binding Letter of Intent on July 15th, 2021. Since signing the LOI, the company has been limited in exercising the buyback plan due to the material nonpublic information of this transaction. Currently, the company is also in black out period due to the 4Q21 results. Once out of the blackout period, the company plans to execute its buyback program.

16:02 EST BrightView acquires Performance Landscapes, terms not disclosed - BrightView Holdings announced the acquisition of Performance Landscapes, a commercial landscaping company headquartered in Honolulu, Hawaii. Terms of the transaction were not disclosed. "Hawaii's landscapes are renowned for their beauty and cultural significance, something we came to appreciate through our Development Services team's work in Hawaii," said Andrew Masterman, BrightView President and Chief Executive Officer. "BrightView is excited to add maintenance services to its existing Development capabilities on the islands."

14:49 EST Axcella poised for 'transformational year,' CEO Hinshaw says - Axcella (AXLA) is a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using endogenous metabolic modulator compositions. In an exclusive interview with The Fly, CEO Bill Hinshaw discussed the company's year ahead: "Axcella is poised for a transformational year. We have two major data readouts in long COVID and in 1125 with NASH. These are very important diseases with high unmet needs. We are compelled and excited as a company. We believe we have high information, higher probability of success and a number of important transformational data readouts in the near-term," the executive explained. "Meet the Company" is The Fly's recurring series of exclusive short interviews with Executive Officers to offer a deeper look inside the company.

14:39 EST Axcella CEO says AXA1665 program in OHE 'underway and screening patients' - Axcella (AXLA) is a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using endogenous metabolic modulator compositions. In an exclusive interview with The Fly, CEO Bill Hinshaw discussed the company's AXA1665 for the treatment of overt hepatic encephalopathy, or OHE: "This program is underway and screening patients actively. We've had high engagement from medical community because they understand that this product has the opportunity to first improve on the standard care and then become the standard care because of its multitargeted, well differentiated, safe and well tolerated profile. OHE is a rarer disease than NASH or long COVID, and we're working with the investigators to make sure we identify the right patients, screen against them and then treat them appropriately with the 1665 compared to the standard of care," the executive explained. "Meet the Company" is The Fly's recurring series of exclusive short interviews with Executive Officers to offer a deeper look inside the company. The remainder of this interview to follow.

14:14 EST Axcella CEO says long COVID trial 'going very well,' sees data in middle of 2022 - Axcella (AXLA) is a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using endogenous metabolic modulator compositions. In an exclusive interview with The Fly, CEO Bill Hinshaw talked about the company's AXA1125 Phase 2a trial in long COVID: "The trial is going very well. We've initiated and started dosing patients. There is a tremendous interest both with patients as well with the medical community because unfortunately there are no proven options for patients with long COVID, there is very little in development and a tremendous need from a number standpoint - we now have 70M people globally estimated to have long COVID - fatigue is the most common symptom and has a huge impact both on society as they can't return to work and a human element. We're talking about mothers who longer able to feel like they're fulfilling their purpose, physicians who had their careers taken from them and athletes who are now in wheelchairs. It's a very large need and thus we've had a tremendous response and we're on track to report our data in the middle of this year. We're extremely excited and compelled by this need. The need is there so the opportunity to help people is there. Unfortunately, the numbers are quite staggering - an estimated of 70 million people with long COVID and that is growing dramatically with the increases we're seeing recently. Now, of those a majority suffers from fatigue. We're talking about over 35M worldwide. When you translate that into the United States, you're talking about more than 15M people with long COVID and more than 7.5M already suffering from some form of fatigue. We're testing this with the Phase 2a trial partnered with Oxford. We look at data in the middle of this year and hopefully we will provide a solution to these patients who are suffering and need help," the executive explained. "Meet the Company" is The Fly's recurring series of exclusive short interviews with Executive Officers to offer a deeper look inside the company. The remainder of this interview to follow.

14:00 EST Axcella's Hinshaw has seen no major COVID-related impacts to trials

14:00 EST Axcella CEO expects major data readouts this year in long COVID, NASH

13:47 EST Verizon says voluntarily decided to limit 5G network around airports - Verizon issued the following statement about its planned launch of its 5G Ultra Wideband network: "Verizon is proud to lead the nation in 5G. Tomorrow, Verizon will launch its 5G Ultra Wideband network which will enable more than 90 million Americans to experience the transformative speed, reliability and power of this game-changing network on the go or in their homes or businesses. Americans have been clamoring for 5G and tomorrow we will deliver it. As the nation's leading wireless provider, we have voluntarily decided to limit our 5G network around airports. The Federal Aviation Administration -FAA - and our nation's airlines have not been able to fully resolve navigating 5G around airports, despite it being safe and fully operational in more than 40 other countries. Thanks to the best team in the industry for delivering this technology which promises a revolutionary next step in wireless communications including tremendous benefits for our nation."

13:13 EST YouTube's global head of originals Susanne Daniels to leave, says Kyncl

12:59 EST GWG Holdings trading halted, volatility trading pause

12:30 EST AT&T temporarily defers turning on 'limited number' of 5G towers - AT&T said in a statement to media outlets: "At our sole discretion, we have voluntarily agreed to temporarily defer turning on a limited number of towers around certain airport runways as we continue to work with the aviation industry and the FAA to provide further information about our 5G deployment, since they have not utilized the two years they've had to responsibly plan for this deployment."

12:07 EST Verizon, AWS expand to 30% more metro area locations with mobile edge computing - Verizon (VZ) and Amazon's (AMZN) AWS are now offering mobile edge computing in more U.S. metro areas with the addition of Charlotte, Detroit, Los Angeles and Minneapolis, the companies announced. "Verizon 5G Edge with AWS Wavelength, a real-time cloud computing platform, brings AWS compute and storage services to the edge of Verizon's wireless network. The combination minimizes the latency and network hops required to connect from an application hosted on the platform to the end user's device. Launched in August 2020, the companies currently offer mobile edge computing via AWS Wavelength Zones in 17 locations in the U.S. Using 5G Edge with AWS Wavelength allows developers and businesses to build and deploy a variety of applications such as machine learning, Internet of Things, and video and game streaming," the companies said.

12:00 EST Sweetgreen falls -12.9% - Sweetgreen is down -12.9%, or -$3.38 to $22.83.

12:00 EST BIT Mining Limited falls -27.1% - BIT Mining Limited is down -27.1%, or -$1.33 to $3.58.

12:00 EST Fathom rises 9.1% - Fathom is up 9.1%, or 72c to $8.61.

11:51 EST East Stone Acquisition Corp trading resumes

11:46 EST East Stone Acquisition Corp trading halted, volatility trading pause

11:32 EST Ford, ADT Inc. form joint venture for vehicle security - Ford (F) and ADT Inc. (ADT) will invest in a new joint venture called Canopy that combines ADT's professional security monitoring and Ford's AI-driven video camera technology to help customers strengthen security of new and existing vehicles across automotive brands. Canopy plans to launch industry-first, multi-sensor security systems with available professional monitoring early next year. The first products to be manufactured and sold will be available in the U.S. and the U.K. for the industry's highest-volume commercial and retail pickups and vans - including the Ford F-150, F-150 Lightning, Transit vans and E-Transit - and will be easily installable by customers to protect expensive work and recreational equipment. Canopy also plans to begin integrating camera security solutions in Ford vehicles next year for seamless protection inside and outside vehicles. Canopy will seek factory-vehicle integrations with other automakers over time. The Canopy team has been developing and testing its first technologies for two years as part of Ford's New Business Platform innovation incubation group. They will now be headquartered in Detroit and London and led by Interim CEO Christian Moran. Canopy also will seek relationships with other automotive, insurance, and technology companies to expand offerings, explore insurance benefits for use of the technology, and co-create new innovations. Ford and ADT's investment in Canopy is subject to certain conditions, including regulatory approvals, and initial funding is expected to close in the second quarter of 2022. The partners expect to invest approximately $100 million during the next three years.

11:07 EST Sirius XM announces multi-year extension to broadcasting agreement with PGA Tour - The PGA Tour and SiriusXM announced that they have reached a multi-year extension to their broadcasting agreement, which will continue to deliver tournament coverage on the SiriusXM PGA Tour Radio channel for subscribers nationwide through 2024. "We are very pleased to extend our relationship with the PGA Tour. Our extensive schedule of in-depth tournament broadcasts will continue to ensure golf fans can follow the best players in the world as they compete all season long. With live event broadcasts every week, and a daily original programming lineup that features some of the most entertaining voices in the game, the best golf coverage in audio entertainment, bar none, continues to be on SiriusXM," said Scott Greenstein, SiriusXM's President and Chief Content Officer.

10:31 EST Douglas Elliman appoints Deva Roberts SVP, associate general counsel - Douglas Elliman Realty announced that Deva Roberts has been named the firm's new Senior Vice President and Associate General Counsel. In this role, she will be engaged in all legal aspects of the firm's real estate sales and development work. Roberts will work from Douglas Elliman's corporate headquarters at 575 Madison Avenue, the company said in a statement.

10:02 EST P&F Industries acquires business of Jackson Gear Company for $2.3M in cash - P&F Industries announced that effective January 15, through a wholly owned subsidiary of Hy-Tech Machine, it acquired substantially all the non-real estate assets comprising the business of Jackson Gear Company, a Pennsylvania-based corporation that manufactures and distributes custom gears and power transmission gear products. The purchase price consisted of an aggregate of $2.3M in cash and the assumption of certain payables and obligations.

10:00 EST BIT Mining Limited falls -14.5% - BIT Mining Limited is down -14.5%, or -71c to $4.20.

10:00 EST BP Prudhoe Bay rises 7.4% - BP Prudhoe Bay is up 7.4%, or 39c to $5.65.

10:00 EST Fathom rises 7.5% - Fathom is up 7.5%, or 59c to $8.48.

09:53 EST Diana Shipping reports continuation of time charter contract for Polymnia - Diana Shipping announced that, through a separate wholly-owned subsidiary, it has extended the time charter contract with CLdN Cobelfret SA, Luxembourg, for one of its Post-Panamax dry bulk vessels, the m/v Polymnia. The gross charter rate is $24,750 per day, minus a 5% commission paid to third parties, for a period until minimum January 15, 2023 up to maximum March 15, 2023. The new charter period is expected to commence on February 2, 2022. The m/v Polymnia is currently chartered, as previously announced, at a gross charter rate of $12,100 per day, minus a 5% commission paid to third parties. The "Polymnia" is a 98,704 dwt Post-Panamax dry bulk vessel built in 2012. The employment of "Polymnia" is anticipated to generate approximately $8.49M of gross revenue for the minimum scheduled period of the time charter.

09:50 EST Goldman Sachs committed to paying more for top talent, says CFO Coleman

09:48 EST Docebo, Pavilion enter strategic partnership to enhance learner experience - Docebo and Pavilion announced that they have entered a strategic partnership to enhance the learner experience for Pavilion's members. This partnership includes several Docebo products that will enable Pavilion to further support its 7,000+ members through additional training and certification opportunities and valuable content offerings, resources, and learning experiences through Pavilion University, powered by Docebo.

09:47 EST Missouri American Water invests $52M to replace St. Louis County pipes - To improve St. Louis County's aging water system, Missouri American Water is replacing nearly 95,000 feet of water main starting in January. "Over the next few months, we are investing $52 million in pipe replacement across St. Louis County to increase service reliability for our customers and enhance fire flow for our firefighters," said Missouri American Water President Rich Svindland.

09:47 EST Unilever falls -9.7% - Unilever is down -9.7%, or -$5.26 to $49.03.

09:47 EST Bancolombia rises 6.2% - Bancolombia is up 6.2%, or $2.07 to $35.32.

09:47 EST Direxion Daily Semiconductor Bear 3X Shares rises 6.9% - Direxion Daily Semiconductor Bear 3X Shares is up 6.9%, or 24c to $3.72.

09:46 EST PNC Financial sees FY22 revenue up 8%-10%, consensus $20.59B - Sees FY22 average loans up 10%. Sees FY22 period-end loans up 5%. Sees FY22 noninterest expense ex-items up 4%-6%. Sees FY22 effective tax rate 18%. Guidance taken from Q4 earnings conference call.

09:45 EST Goldman Sachs CEO sees omicron having less of an economic impact

09:38 EST SpartanNash names Bennett Morgan as SVP, Chief Merchandising Officer - SpartanNash (SPTN) announced the addition of Bennett Morgan to its executive leadership team. Morgan will serve as Senior Vice President and Chief Merchandising Officer, effective Jan. 24 and reporting to SpartanNash President and CEO Tony Sarsam. Morgan joins SpartanNash from Amazon (AMZN), where he helped launch its fast-growing grocery business, including opening physical stores across the country.

09:37 EST Goldman Sachs CEO: Inflation may be above trend for some time

09:31 EST Atossa Therapeutics announces advancement to Part B of AT-H201 study - Atossa Therapeutics announces it is advancing to enroll participants in Part B of its Phase 1/2a clinical study of AT-H201 in Australia, consisting of multiple ascending dose cohorts in healthy participants. The nebulized formulation, AT-H201, is being developed as an inhalation therapy for moderately to severely-ill hospitalized COVID-19 patients and for "long-haul" patients with post-infection pulmonary disease. Part A of the study, which consisted of a single ascending dose group of 4 cohorts of healthy participants, has now been completed. The Australian Human Research Ethics Committee has reviewed the safety data from Part A and has approved the study to proceed to Part B. The Phase 1/2a placebo-controlled study will enroll a total of 60 healthy participants and moderately-ill hospitalized COVID-19 patients. The study has 4 parts: Part A - a single ascending dose part, Part B - a multiple ascending dose part, Part C - a combination part in healthy individuals, and Part D a combination in COVID-19 infected patients. The study is being conducted by Avance Clinical Pty Ltd., a leading Australian clinical research organization. AT-H201 is a proprietary combination of two drugs previously approved by the FDA to treat other diseases and by other administration routes. AT-H201 is intended to be inhaled via a nebulizer to improve compromised lung function for moderate to severely ill, hospitalized COVID-19 patients and for "long-haul" patients with post-infection pulmonary disease. In May 2020, we completed in vitro testing of AT-H201 which showed that the components of AT-H201 inhibit SARS-CoV-2 infectivity of VERO cells, which is a standard cell type being used to study infectivity of the coronavirus. The Phase 1/2a study in Australia and other clinical studies must be successfully completed and regulatory approvals must be obtained before AT-H201 may be commercialized. No assurance can be given than studies will be successful or that regulatory approvals will be obtained.

09:29 EST Biofrontera Inc. 'poised' to increase sales, gain further market share - The company said, "We would like to extend warm wishes to all of you for a healthy and prosperous 2022. At Biofrontera Inc., we welcomed the New Year with optimism and continued business momentum..We are proud of the hard work by the talented members of our sales team across the country. Despite the challenges resulting from the COVID-19 pandemic, we returned to topline growth in 2021. Most dermatology offices have fully reopened and patients have shown increased willingness to undergo in-office treatments for AK. We exited 2021 with strengthened financial performance, including: Preliminary sales for the fourth quarter of 2021 in a range of $9.1 million to $9.2 million, representing an increase of approximately 7% compared with the fourth quarter of 2020. Preliminary revenue for the full year 2021 anticipated to be in the range of $24.1 million to $24.2million, an increase of approximately 27% over full year 2020...According to the Skin Cancer Foundation, AK affects approximately 58 million people in the U.S. In 2020, an estimated 12.7 million AK treatments were performed in the U.S., which translates to a total addressable market of about $4 billion for Ameluz with its current FDA-approved indication. AK is a precursor to squamous cell carcinoma, a skin cancer with a potentially fatal outcome. The most common treatment for AK is cryotherapy, with a 2020 market share of approximately 86%. Topical drugs for the treatment of AK had a market share of about 12%, followed by photodynamic therapy treatments with about a 2% share. Despite its market dominance, we think cryotherapy lacks certain advantages as a treatment option compared with PDT. As such, the opportunity to gain share from cryotherapy is a key focus of our commercial efforts. Expanding the Ameluz label allows us to consistently deliver innovative solutions for patients and serves as the key mechanism to unlock the drug's potential. Continued investment in clinical research by our license partner aiming at label expansion is thus an integral part of our business. According to our license agreement for Ameluz, the licensor is obliged to conduct and finance the clinical studies required for defined label expansions. The FDA approval pathway takes significant investment and time but, if successful, the result can be very rewarding - not only for the patients, but also for the potential value creation for our shareholders. The clinical successes for our licensed products in 2021 included regulatory approval for the new RhodoLED XL lamp, progress on the Phase 3 study for the treatment of basal cell carcinoma, the launch of a 3-tube safety study as well as a Phase 2b trial for acne - all of which keep the Ameluz clinical program moving forward. Our second licensed prescription drug is Xepi. Xepi is a topical antibiotic for the treatment of impetigo, a highly contagious bacterial skin infection with more than 3 million cases in the U.S. each year. Currently, no antibiotic resistance against Xepi is known, and Xepi has also been specifically approved by the FDA for resistant strains of staphylococcus aureus or streptococcus pyogenes, including MRSA. In 2020, more than 13 million prescriptions were written for drugs in indications where Xepi could be effective. Xepi is distributed through specialty pharmacies and is generally covered by most commercial payers without pre-authorization. We believe there is considerable market potential for Xepi in the coming years..Our longer-term financial objectives include achieving consistent revenue growth and expanding operating margins. Accordingly, we are focused on balancing market expansion with operating efficiency, including effective resource utilization, information technology leverage and overhead cost management. Our market-expansion strategy is based on bolstering awareness of our licensed products through industry recognition, data-driven sales strategies, and a robust and dynamic commercial infrastructure. We intend to optimize our sales force by adding sales territories, and to strengthen medical affairs to become a trusted partner through scientific data publication, interaction with key opinion leaders and industry support. Overall, our marketing and development goals align to form a commercial strategy that has uniquely positioned Biofrontera for leadership in the treatment of dermatological conditions. As we move into 2022, the energy across our organization is palpable. We are poised to increase sales and gain further market share in the U.S. We intend to expand our corporate footprint and to invest in our long-term growth strategies. As we continue to build upon our position in the dermatology market in the U.S., we invite you along on our exciting journey and affirm our commitment to transparency on the progress and milestones we strive to achieve."

09:26 EST SPAC Yellowstone, Sky Harbour announces $70M FP deal in connection to deal - "Sky Harbour which aims to address the shortage of private aviation hangars in many areas across the country by establishing a network of turnkey upscale business aviation hangar complexes, and Yellowstone Acquisition Company a publicly-traded special purpose acquisition company announced that in connection with their proposed business combination , Yellowstone has entered into a forward purchase agreement for up to $70M with an affiliate of Atalaya Capital, a privately held, SEC-registered alternative investment advisory firm that focuses primarily on private credit and special opportunities investments. On January 17, Yellowstone and ACM ARRT VII E , entered into an agreement or FPA for an Equity Prepaid Forward Transaction FP Transaction...The number of Subject Shares shall be no more than the lesser of 7,000,000 and the maximum number of Shares such that Seller does not beneficially own greater than 9.9% of the Shares on a post-combination pro forma basis. If the Seller acquires less than 2,500,000 Subject Shares, it has agreed to acquire additional Shares from the Company in a private placement which will be subject to the FPA such that the sum of the number of Additional Shares and the number of Subject Shares will be equal to 2,500,000.

09:19 EST Qualigen secures worldwide rights to G4-selective transcription inhibitors - Qualigen Therapeutics announces the exclusive worldwide in-license of a genomic quadruplex, G4,-selective transcription inhibitor drug development program, including lead and back-up compounds, preclinical data and a patent estate, from University College London. Qualigen intends to develop the lead compound, now called QN-302, as a treatment for pancreatic ductal adenocarcinoma, PDAC, which represents the vast majority of pancreatic cancers. This license agreement was carried out by UCL Business Limited, the commercialization company for UCL. "QN-302 is a promising candidate with a novel mechanism of action, supported by preclinical data from one of the leading pharmacology institutions in the world. This program aligns with our oncology focused therapeutics pipeline, expands our IP portfolio, and positions Qualigen well in this exciting area of G4 cancer research," commented Michael Poirier, Qualigen's Chief Executive Officer. "The scientific work UCL completed on the G4 platform could enable us to proceed with IND-enabling studies in 2022 toward an initial indication of pancreatic cancer."

09:17 EST Blue Hat Interactive subsidiary Xunpusen expands cooperation with JD Cloud - Blue Hat Interactive announced the expansion of the cooperation between the company's operating subsidiary, Xunpusen Technology, and JD Cloud, a cloud computing brand under JD Technology, following JD Cloud's authorization of Xunpusen as one of its core channel partners. In October 2021, Xunpusen signed an agreement to be a channel and port provider for JD Cloud's SMS channels services.

09:16 EST Natural Alternatives International raises share repurchase plan by $3M - Natural Alternatives International announced its Board of Directors authorized a $3M increase to its stock repurchase plan bringing the total plan authorized repurchase amount to $18M. Under the repurchase plan, NAI may, from time to time, purchase shares of its common stock, depending upon market conditions, in open market or privately negotiated transactions. "To date, we have purchased 1.9 million shares under this repurchase plan, including the purchase of 237,000 shares since September 30, 2021, and after this increase we will have $3.0 million available for stock repurchases under the plan."

09:16 EST Clarus Therapeutics appoints Zhanna Jumadilova as chief CDO - Clarus Therapeutics announced the appointment of Zhanna Jumadilova, M.D., M.B.A., as Chief Clinical Development Officer, effective January 17, 2022. Prior to joining Clarus, Dr. Jumadilova served as Vice President, Clinical Development Head, ALIS at Insmed, a global biopharmaceutical company focused on the unmet needs of patients with rare diseases.

09:15 EST Altice USA, Ampersand announce multi-faceted partnership - Ampersand announced a multi-faceted partnership with leading Linear TV distributor, Altice USA. Ampersand becomes the exclusive seller of Altice's national Addressable inventory and will also integrate aggregated set-top box data insights from two million Altice households with a commitment to protecting personal information into its AND Platform for both local and national Addressable TV planning, buying and measurement. AND, a multiscreen TV planning, buying and measurement platform launched at the beginning of 2020, accounts for the single largest source of TV inventory in the industry, encompassing linear and streaming TV. The AND Platform provides marketers with reach across 80M households, of which 52M are Addressable.

09:14 EST QuickLogic sees Q4 at or above operating cash breakeven - QuickLogic has received an approximately $1M non-cancellable and non-refundable purchase order in December to supply ArcticLink III BX display interface bridging device to a global provider of imaging products. Revenue is expected to be recognized in the first half of FY22. The company expects to be at or above operating cash breakeven in Q4. All other Q4 financial results expected to be within the ranges provided in the conference call held on November 17. Greater interface bridging sales expected further increases confidence in FY22 financial outlook. Global supply chain problems brought on by the COVID-19 pandemic have created a worldwide shortage of certain display bridge semiconductor solutions.

09:13 EST Pentwater Capital sends letter to Turquoise Hill board, urges action - On January 13, Pentwater Capital Management LP, the largest minority shareholder of Turquoise Hill Resources (TRQ), sent the following letter to the members of the Board of Directors of Turquoise Hill. "As with every other letter we have sent for the past year, there was no response. Pentwater urges all Turquoise Hill shareholders to make their voices heard by reaching out directly to the members of the TRQ Board. A copy of the letter is as follows: Dear Board of Directors of Turquoise Hill Resources: As you know, we at Pentwater Capital Management have been your largest minority shareholders for many years. I write to you because weeks have passed since a resolution was voted on in the Mongolian Parliament that could have materially detrimental effects on TRQ, and yet we have not heard any comment from TRQ's Board or management. As a result, we are gravely concerned that you and your cohorts at Rio Tinto (RIO) may be on the verge of committing some or all of the following flagrant derelictions of fiduciary duty: (1) TRQ would agree to forgive $2.3bn in debt that the Government of Mongolia owes TRQ, half of which the minority shareholders will have to absorb even though the only basis to forgive any debt is the malfeasance and misconduct committed by the operator of the mine, Rio Tinto; (2) You have not secured for TRQ minority shareholders any compensation from Rio Tinto in return for the costs and damages they suffered at the hands of Rio Tinto despite the fact that TRQ owns twice as much of the mine as the Mongolian government and the Mongolian government is receiving a package worth well in excess of $2.5 billion; (3) You are going to allow Rio to settle on terms that will restrict you from raising debt at the OT level and require you to fund the whole underfunding needed to complete the project, further harming the TRQ minority investors. If this does, in fact, turn out to be the outcome, you should steadfastly refuse to sign such a deal, and should resign if need be. Over the years, numerous Mongolian government officials - including two Prime Ministers - have been held in jail related to their actions regarding OT; Rio Tinto personnel have had to leave Rio under a cloud of scandal, while the recent independent consultant's report is damning regarding Rio Tinto's actions. Nevertheless, TRQ board members have acted like puppets of Rio Tinto. There is so much blame to go around. Signing off on any of the scenarios listed above would constitute your admission of liability for such a blatant disregard for your fiduciary duties to your shareholders. As a significant investor in Turquoise Hill equity, Pentwater does not prefer to see the underground cease operations. But it is preferable to have a pause in operations than to have you practically give away the mine. Agreeing to the proposal that seems to be on the table would simply be an audacious and astonishing disregard for duty, and the blame would rest at your feet. Rio is desperate to sweep their malfeasance under the rug and will eventually agree to appropriate economic compensation even if it is necessary to pause construction. This mine will eventually operate and will be a windfall to the people of Mongolia and TRQ's investors. The minority shareholders have borne the burden of financing the construction and have had to live with consequences of Rio's misconduct and should be reasonably compensated for such. The minority shareholders continue to carefully watch your actions. You will surely be held to account for breaches of your fiduciary duties. We have seen enough from your past actions to not have much hope of our pleas leading to any result. With that said, it is never too late to begin doing the right thing. Please publicly reply to this letter and release this letter along with your response."

09:12 EST Revelation announce first patient enrolled, dosed in Phase 1b study of REVTx-99 - Revelation Biosciences announced that the first patient has been enrolled and dosed in a Phase 1b clinical study to evaluate the potential utility of REVTx-99 for treating patients with allergic rhinitis and patients with chronic nasal congestion without polyps. The clinical study is being conducted in Australia. "In the US, approximately 8% of adults and 7% of children have allergies that cause symptoms of allergic rhinitis, also called hay fever, and patients with allergic rhinitis have a threefold greater risk of developing asthma. The risk of developing asthma increases with more severe and persistent allergic rhinitis," said James Rolke, Chief Executive Officer of Revelation. "REVTx-99 is being developed as a therapy for the millions of people who suffer from these symptoms each year." The Phase 1b, randomized, double-blind, placebo-controlled, crossover design study is expected to enroll approximately 28 participants. The primary endpoint is to evaluate the effects of REVTx-99 versus placebo on safety and tolerability. Key secondary endpoints include allergy symptoms and peak nasal inspiratory flow elicited by nasal allergen challenge. The company expects the topline data in the first half of 2022.

09:11 EST ENGlobal receives $2.2M in purchase orders to build security trailers - ENG announced it has received purchase orders worth $2.2M to build 120 parking lot security trailers. The trailers, whose primary purpose is to provide electronic surveillance that keeps parking lots safer and which can be used for other remote surveillance, will be built at the company's fabrication facility in Henderson, Texas and assembled in Houston, Texas at its 80,000 square foot indoor integration facility. ENG will build and deliver a minimum of 10 trailers per month starting this month and expects to deliver all 120 trailers by the end of this year. ENG engineered, designed, built and delivered a total of 50 trailers in 2021, receiving revenue of $950,000.

09:10 EST Virpax completes dermal safety studies for Epoladerm for osteoarthritis - Virpax Pharmaceuticals (VRPX) reported positive results of four preclinical dermal safety studies for Epoladerm, diclofenac epolamine. Epoladerm is an investigational product candidate for the management of pain associated with osteoarthritis of the knee. From these recently concluded animal studies, researchers concluded that once daily dermal administration of Epoladerm for 28 days was well-tolerated with no serious adverse findings. The studies were performed by Charles River Laboratories (CRL), a well-known clinical research organization. The studies included a skin irritation study in rabbits; a dermal sensitization assessment in guinea pigs; and a phototoxicity assay in mouse fibroblasts. Epoladerm was well- tolerated in each of the studies and no reportable dermal irritation, dermal sensitization or phototoxicity was observed. "These successful preclinical outcomes should further strengthen Virpax's planned Investigational New Drug Application for Epoladerm in advance of the anticipated start of first-in-human trials," said Anthony P. Mack, Chairman and CEO of Virpax.

09:10 EST Dish Wireless, WCI Technologies announce partnership - WCI Technologies announced a partnership with DISH Wireless to market 5G services to enterprises. This collaboration expands upon a longstanding business relationship between WCI and DISH. WCI will sell, market and deliver systems integration services to enterprise customers while DISH provides access to its deep portfolio of licensed spectrum, RF design capabilities and 5G deployment expertise. The venture will target enterprise customers across oil and gas, health care, mining and other industries. The combined offering with WCI will initially focus on private wireless solutions supported by DISH's portfolio of licensed spectrum. Customers with mission-critical business functions requiring wireless connectivity will be able to maintain complete control over the management of their networks without the risk of uncertain performance that is inherent in shared spectrum options. Once DISH launches its 5G network, the partnership with WCI will expand to include support for handsets and data devices that require nationwide coverage.

09:08 EST Romeo Power names Anne Devine as COO, Rose Rogers as CPO - Romeo Power announced that it has named Anne Devine as COO and Rose Rogers as chief people officer. In their new executive roles Devine and Rogers will report directly to CEO Susan Brennan. Devine will replace Criswell Choi, who will leave Romeo after a four-week transition period to pursue other opportunities.

09:08 EST Praxis Precision Medicines announces publication of PRAX-562 preclinical data - Praxis Precision Medicines announced the publication of data in the journal Epilepsia from a preclinical study of PRAX-562, a preferential persistent sodium channel blocker currently in development for the potential treatment of rare adult cephalgias and Developmental and Epileptic Encephalopathies. This preclinical study investigated the effects of PRAX-562 on intrinsic neuronal excitability and protection from induced seizures as compared to sodium channel blockers used as standard-of-care antiepileptic treatments. In the study, PRAX-562 demonstrated robust preclinical antiseizure activity and significantly improved preclinical tolerability, with improved or comparable efficacy when evaluated against currently used sodium channel blockers. The data demonstrate that by preferentially blocking persistent sodium current, PRAX-562 may represent a differentiated treatment option for disorders of hyperexcitability, such as DEEs, where standard sodium channel blockers are effective but poorly tolerated. DEEs are a group of disorders characterized by intractable seizures and other co-morbidities. Mutations in voltage-gated sodium channel genes are the most common causes of DEEs. Given the number of NaV-targeting antiepileptic drugs, and the well understood role of sodium channels in governing brain excitability, it is clear that mutations and other causes of sodium channel dysregulation contribute to the pathology of DEEs and other, more common, forms of epilepsy.

09:07 EST Castor Maritime announces $55M debt financing, charter agreement - Castor Maritime announces the closing and drawdown of a $55.0 million senior term loan facility with a European bank, through, and secured by, five of its dry bulk vessel ship-owning subsidiaries and guaranteed by the Company. The Company intends to use the net proceeds from the $55.0 Million Financing for general corporate purposes, including supporting the Company's growth plans. The $55.0 Million Financing has a tenor of five years and bears interest at adj. SOFR plus 3.15% per annum. The M/V Magic Callisto, a 2012 built Panamax dry bulk carrier, has been fixed on a time charter contract at a gross daily charter rate equal to 101% of the average of the Baltic Panamax Index 4TC routes1. The charter commenced on January 12, 2022, and has a minimum duration of nine months and a maximum duration of about twelve months at the charterer's option. The benchmark vessel used in the calculation of the average of the Baltic Panamax Index 4TC routes is a non-scrubber fitted 74,000mt dwt vessel with specific age, speed - consumption, and design characteristics.

09:06 EST American International appoints Lorraine D'Alessio, Kenny Myers to board - American International announced that the Board of Directors has appointed Ms. Lorraine D'Alessio and Dr. Kenny Myers to fill two of the vacancies on the Board of Directors, as independent directors. With these appointments, the Company's Board of Directors now has four members, three of which are independent. Both Ms. D'Alessio and Dr. Myers were also appointed to serve as members of the Company's Audit Committee. Since 2010, Ms. D'Alessio has served as CEO and Managing Partner at D'Alessio Law Group, PLC, a law firm in Beverly Hills, California which provides immigration and entertainment law services. Since March 2020, Dr. Myers has served as an owner and Vice President of Business Development for Living Fit Nation, Inc., a corporate wellness provider which designs and implements customized employee health and wellness programs for corporations, schools and municipalities around the United States.

09:05 EST Fortinet announces Home Hardware has implemented Fortinet Secure SD-WAN - Fortinet announced Home Hardware has implemented Fortinet Secure SD-WAN to digitally transform their organization. Over the past few decades, Home Hardware has grown dramatically to around 1,100 Dealer-owned stores as well as multiple data centers and cloud environments. "After an extensive evaluation process that included multiple vendor solutions, Fortinet Secure SD-WAN emerged as the right choice for Home Hardware," the company said. By tapping into the power of Fortinet Secure SD-WAN, Home Hardware is taking a security-driven networking approach to their digital transformation efforts to realize the following benefits: Better user experience, Simplified operations and reduced complexity, and Ensured PCI compliance.

09:02 EST Satellogic, CF Acquisition Corp. V secures additional $150M private placement - Satellogic and CF Acquisition Corp. V announced that they have secured an additional $150M private placement commitment from Liberty Strategic Capital, a private equity firm founded and led by former U.S. Secretary of the Treasury Steven Mnuchin. This investment brings the total committed capital coming into Satellogic in this series of transactions to more than $265M, building on the previously announced PIPE offering of $100M led by SoftBank's SBLA Advisers Corp. and Cantor Fitzgerald, among other top-tier institutional investors. Cantor Fitzgerald has increased its PIPE participation to approximately $58M from the previously disclosed amount of $33M. Both the Liberty and SoftBank SBLA Advisers Corp. placements are subject to lock-up provisions for a minimum of a year. In connection with Liberty's investment in Satellogic, Secretary Mnuchin will join Satellogic's board of directors as non-executive chairman. Chairman and CEO of Cantor Fitzgerald and CFV Howard Lutnick will also join the board of directors.

09:02 EST NeuroMetrix receives FDA Breakthrough Designation for Quell technology - NeuroMetrix announced that its Quell technology has received Breakthrough Designation from the U.S. Food and Drug Administration, FDA, for reducing moderate to severe symptoms of chemotherapy induced peripheral neuropathy that have persisted for at least 6-months following the end of chemotherapy. Quell is an advanced, non-invasive, neuromodulation technology that is covered by 19 U.S. utility patents. It is the only wearable neuromodulator that is enabled by a proprietary microchip that provides precise, high-power nerve stimulation in a form factor the size of a credit card. The Quell device utilizes position and motion sensing to automatically adjust stimulation for an optimal patient experience both day and night. "This Breakthrough Device Designation is an important step in our effort to make Quell technology available to patients suffering from the debilitating effects of CIPN," said Shai Gozani, M.D., Ph.D., CEO of NeuroMetrix. "We are looking forward to completion and subsequent reporting of the results from the ongoing multi-center RCT of Quell in CIPN. Depending on the outcome of the trial, we hope to be positioned for an FDA filing in 2023. Following on our first Breakthrough Designation for fibromyalgia, this new designation for CIPN advances our effort to build a portfolio of Quell based prescription wearable neurotherapeutics."

08:59 EST Cummins completes 50% acquisition of Momentum Fuel from Rush Enterprises - Cummins (CMI) and Rush Enterprises (RUSHA) announced that they have closed on Cummins' acquisition of 50% equity interest in Momentum Fuel Technologies from Rush Enterprises. The joint venture between Rush Enterprises and Cummins will seek to enhance production of near-zero emissions natural gas powertrains by manufacturing Cummins-branded natural gas fuel delivery systems for the commercial vehicle market in North America. The new company combines the strengths of Momentum Fuel Technologies' compressed natural gas fuel delivery systems and Cummins' powertrain expertise. When powered by renewable natural gas, using methane collected from organic waste as the primary fuel source, the engines can be credited with a neutral to negative carbon index, resulting in net greenhouse gas emissions at or below zero. The joint venture will offer aftermarket support through Rush Truck Centers dealerships and Cummins distributors which will be able to service both the engine and the fuel delivery system. The partnership between Cummins and Rush Enterprises will benefit customers by providing them with access to an extensive CNG vehicle parts and service network; both Cummins' and Rush Enterprises' respective networks, which together represent over 250 locations in the US and Canada, will be equipped with certified technicians and access to a comprehensive CNG vehicle parts inventory.

08:51 EST Allegro MicroSystems announces A19360 wheel speed, distance sensor - Allegro MicroSystems announced its new A19360 wheel speed and distance sensor for use in emerging applications in advanced driver assistance systems. The cutting-edge giant magnetoresistance sensor provides automakers with the signal resolution and reliability required for advanced levels of automation in passenger vehicles and mobility-as-a-service applications.

08:50 EST Celestica's U.S. facility certified to ISO 13485 for medical device manufacture - Celestica announced its AbelConn Electronics facility in Maple Grove, MN, has earned ISO 13485:2016 certification for medical device production. The certification expands Celestica's global expertise in design and manufacturing to drive market-leading quality and regulatory compliance for our global healthcare customers.

08:49 EST Barfresh Food Group announces uplisting to Nasdaq Capital Market - Barfresh Food Group announced that its shares of common stock have been approved for listing on The Nasdaq Capital Market. Trading on Nasdaq is expected to commence on January 20, 2022 under the symbol "BRFH".

08:47 EST Datasea announces research partnerships to focus on acoustic intelligence - Datasea announced that it has entered into partnerships with Chinese leading research institutes to "unlock the full potential of acoustic intelligence in the commercial applications," the company said. The Company released China's inaugural white paper with co-authors, Institute of Cloud Computing and Big Data, China Academy of Information and Communications Technology to uncover detailed facts and compelling analyses of the acoustic-intelligence technology, commercial applications, and the industry outlook. Datasea has entered into partnerships with leading institutions in China with the aim of 1) promoting the formulation of acoustic intelligence technology standards and expanding the leadership in the industry; 2) building an ecosystem to expedite research and development of new products; and 3) enhancing research capability and talent retention for the Company in the long run. Datasea's research partners include Acoustics Research and Communication Laboratory of the Chinese Academy of Sciences, the Cloud Computing and Big Data Institute of the China Academy of Information and Communications Technology, and Beijing Union University. In the white paper entitled "Industry Development and Technology Application of Acoustic Intelligence in China," Datasea dives into the current and future use cases of acoustic intelligence in China and outlines the introduction of acoustic intelligence, technology development, commercial applications and industry outlook to provide technical insights and guide industry development. To date, Datasea has completed the technology development, product design, supply chain management and marketing plans for a series of acoustic hardware products in six major industries and application areas, including but not limited to healthcare, medical beauty, environmental protection and agriculture. The three flagship products, including Tianer voice recognition alarm, ultrasonic sound sterilization and antivirus equipment, and brain refreshing acoustic equipment are expected to be introduced to the market in fiscal year of 2022.

08:45 EST Rafael announces enrollment, additional sites for Phase 2 trial of CPI-613 - Rafael Pharmaceuticals announced the ongoing successful enrollment rate of its Phase 2 clinical trial for CPI-613 in combination with gemcitabine and cisplatin in patients with biliary tract cancer. The multicenter trial is for patients with locally advanced unresectable or metastatic biliary tract cancer who have had no prior treatment. "We are pleased that our Phase 2 trial has continued to see a positive enrollment rate, demonstrating devimistat's ability to serve as a catalyst for hope and potential relief to families affected by this harrowing condition," said Sanjeev Luther, President and CEO of Rafael Pharmaceuticals. "We are happy to report a continuation of safety within the trial, as the wellbeing of our patients is our top priority."

08:43 EST Sportsman's Warehouse reports $299.6M sales for eight week period ended Dec. 25 - Sportsman's Warehouse Holdings announced financial highlights for the eight weeks ended December 25, 2021. "I am extremely proud of our team and the execution of our business through the holiday season of 2021." said Jon Barker, Sportsman's Warehouse CEO. "Overall our business showed tremendous strength across all categories despite a difficult comparison in firearms and ammunition. As we put the terminated merger process with Great Outdoors Group, LLC behind us, we are excited about the future and growth potential of the Company." For the eight weeks ended December 25, 2021: Net sales were $299.6 million, which was flat versus the comparable eight weeks of fiscal year 2020. Compared to the same eight-week period of fiscal year 2019, net sales increased 59.3% from $188.1 million. Same store sales decreased 6.1% during the eight weeks of fiscal year 2021 compared to the eight weeks of fiscal year 2020. Excluding firearms and ammunition same store sales increased 2.8% compared to the same eight-week period of fiscal year 2020. Compared to the same eight weeks of fiscal year 2019, same store sales increased 38.7%. Same store sales in the Footwear, Optics/Electronics/Accessories, and Clothing categories increased 15.7%, 6.7%, and 4.4%, respectively, compared to the eight weeks of fiscal year 2020. Ecommerce sales increased 2.5% compared to the same eight-week period of fiscal year 2020. Compared to the same eight-week period of fiscal year 2019, ecommerce sales increased approximately 200%. The Company opened three new stores, which were located in Chandler, AZ; Elk Grove, CA; and Greenwood, IN. The Company received $55 million from the termination of its merger agreement with Great Outdoors Group, LLC and recorded a one-time gain. Balance sheet highlights as of December 25, 2021: Cash on hand of $57.4 million, no long-term debt and $39.9 million outstanding under our revolving credit facility. Total liquidity of $216.1 million, which is comprised of our $57.4 million cash on hand plus $158.7 million available borrowing capacity under our revolving credit facility

08:41 EST Waitr Holdings announces Timothy Newton as Chief Technology Officer - Waitr Holdings announced that Timothy Newton has been named Chief Technology Officer. Mr. Newton brings more than two decades of information technology experience to the position, including stints at Papa John's International and Fat Tuesday. Most recently, Mr. Newton was chief technology officer at Fat Tuesday & New Orleans Original Daiquiris where he was responsible for strategic direction and execution of the company's technology modernization efforts and standards. He also spearheaded the evaluation, selection and implementation of a new point-of-sale solution across 40 corporate locations, providing needed visibility to key store operational metrics.

08:40 EST Marrone Bio issues shareholder letter - Marrone Bio Innovations released an update letter to shareholders from Chief Executive Officer Kevin Helash announcing preliminary financial results for the fourth quarter and fiscal year ended December 31, 2021. "Dear Shareholders... I am pleased to report that fourth quarter 2021 revenues are estimated to reflect growth in the mid-30% range, as compared with fourth quarter 2020 revenues. For the second half of 2021, revenues are estimated to have increased 20+% when compared with revenues in the second half of 2020. On a full year basis, we estimate revenue growth in the low double-digit to mid-teens range for 2021 as compared with 2020, in line with our forecast... We were encouraged by orders placed in the latter part of the quarter, an important indicator of our customers' plans for the first half of 2022. Our seed treatment solutions were in high demand, especially in Europe for Takla - our newly launched bio-nutritional product - and in the United States for BIOSt Bionematicide - a seed treatment for soybeans and corn... As announced previously, we have submitted MBI-306 - our second-generation bioinsecticide/bionematicide - for regulatory approval in the United States. We anticipate this product will deliver peak potential revenue of approximately $100 million per year, with a product launch targeted for 2023/2024... We also recently announced our acquisition of exclusive rights to high-performing strains of a microorganism with a novel mode of action that we believe will accelerate the advancement of our bioherbicide, MBI-006... We remain confident that, going forward, MBI is well positioned to outpace our peers in the ag biological industry."

08:39 EST OSI Systems gets $5M order from 'leading' X-ray imaging OEM - OSI Systems announced that its Optoelectronics and Manufacturing division has received an order for approximately $5M to provide electronic components to a "leading" X-ray imaging original equipment manufacturer . OSI Systems' Chairman and Chief Executive Officer, Deepak Chopra, stated, "We are excited to receive this order and look forward to supporting this customer's growing demand with its medical and industrial markets."

08:38 EST InspireMD announces live case broadcast at ISET 2022 - InspireMD announced that a live case demonstration featuring CGuard EPS will be broadcasted at the International Symposium on Endovascular Therapy 2022 Conference by Dr. Chris Metzger, Chair of Clinical Research at Ballad Health on Tuesday, January 18, 2022. "We are extremely grateful to have been selected and approved for a Live Case Presentation at this year's ISET Conference demonstrating the advantages of CGuard," said Marvin Slosman, Chief Executive Officer of InspireMD. "The global recognition of the CGuard stent system continues to demonstrate clinical evidence and data supporting CGuard's safety and efficacy and we are pleased to have been selected for a live case as an advanced device for treatment of CAD at this important conference."

08:37 EST Aslan Pharmaceuticals to host new episode in A4 KOL Series - ASLAN Pharmaceuticals announced that it will host the second episode in its series of Key Opinion Leader events on the emerging Atopic Dermatitis landscape and ASLAN004, on Thursday, January 20, 2022, at 12:00pm ET. Dr April Armstrong, MD MPH, will be the second KOL to speak at ASLAN's A4 webinar series: Aspects of Atopic Dermatitis and ASLAN004. The webinar will feature a presentation by Dr Armstrong that explores the key clinical study parameters likely to impact patient responses and clinical trial outcomes in AD. Dr Armstrong has conducted over 150 clinical trials and has significant expertise in inflammatory skin diseases, with a specialty in AD. Following Dr Armstrong's presentation, Karen Veverka, PhD, Vice President Medical at ASLAN, will briefly review the Phase 2b study design for ASLAN004, a potential first-in-class antibody targeting the IL-13 receptor alpha1 subunit, one of the components of the Type 2 receptor. By blocking the Type 2 receptor, ASLAN004 prevents signaling through both interleukin 4 (IL-4) and interleukin 13, the key drivers of inflammation in AD. The unique mechanism of action has the potential to deliver a differentiated safety and efficacy profile as well as an improved dosing regimen.

08:36 EST Impel NeuroPharma provides update on Trudhesa launch, INP105 CALM 201 study - Impel NeuroPharma provided updates on Trudhesa nasal spray launch progress and recent business highlights. Since the October 2021 commercial launch, the performance of Trudhesa has exceeded our expectations with over 4,200 prescriptions generated, surpassing the Company's Q4 guidance of 3,000-4,000 prescriptions. To-date Trudhesa accounts for approximately three percent of new branded acute migraine prescriptions among Impel's 2,000 Super Target prescribers. Notably, Super Targets initiate approximately 60,000 branded acute NBRx, representing 34 percent of the total branded acute NBRx market. In addition, during this first quarter of launch, the Company has secured contracts with several leading pharmacy benefit managers in the U.S. which cover approximately 80 percent of U.S. commercial lives. Impel is the first company to harness the benefits of delivery to the upper nasal space to improve the therapeutic potential of CNS therapies. Using Impel's proprietary POD technology, Trudhesa delivers dihydroergotamine mesylate-a proven, well-established therapeutic for acute migraine for adults-quickly to the bloodstream through the vascular-rich upper nasal space. Trudhesa bypasses the gut and reduces potential absorption issues, offering rapid, sustained, and consistent symptom relief without injection or infusion, even when administered hours after the onset of a migraine attack. INP105 CALM 201 Study Update: Impel continues to advance its combination product candidate, INP105, an intranasal olanzapine product being developed as an acute treatment for agitation in persons with autism spectrum disorder via Impel's POD technology. Since filing the investigational new drug application in November of last year, the Company has been working with the U.S. Food and Drug Administration to finalize the Phase 2a proof-of-concept clinical protocol and anticipates the study will start in Q1 2022 with a data readout anticipated in Q4 2022. The "CALM 201" Trial is a Phase 2a, proof-of concept, 2-way, 2-period crossover, double-blind study to evaluate the safety and efficacy of INP105 as an acute treatment versus placebo in people with ASD experiencing agitation. This study will evaluate the safety and tolerability of a single dose of INP105 to that of placebo in adolescents with a diagnosis of ASD. The secondary objective is to explore the effect of treatment with a single dose of INP105 versus placebo in people with ASD experiencing agitation. It was hypothesized that INP105 could be a useful treatment for acute agitation episodes in the ASD population. Acute agitation often manifests in patients with serious underlying mental health conditions such as bipolar I disorder or schizophrenia. Between 1.7 million and 7 million episodes of acute agitation have been reported to occur in U.S. hospitals and emergency room settings each year.1 An ideal medication for acute agitation, according to a 2005 expert consensus is easy-to-administer, non-traumatically administered, provides rapid tranquilization without excessive sedation, has a swift onset of action with sufficient duration to prevent untimely recurrence and has low risk for adverse events and drug interactions.

08:35 EST Microsoft to acquire Activision Blizzard for $95.00 per share in cash - Microsoft (MSFT) announced plans to acquire Activision Blizzard (ATVI), which it calls "a leader in game development and interactive entertainment content publisher," stating that this acquisition will "accelerate the growth in Microsoft's gaming business across mobile, PC, console and cloud and will provide building blocks for the metaverse." Microsoft will acquire Activision Blizzard for $95.00 per share, in an all-cash transaction valued at $68.7B, inclusive of Activision Blizzard's net cash. "When the transaction closes, Microsoft will become the world's third-largest gaming company by revenue, behind Tencent and Sony. The planned acquisition includes iconic franchises from the Activision, Blizzard and King studios like 'Warcraft,' 'Diablo,' 'Overwatch,' 'Call of Duty' and 'Candy Crush,' in addition to global eSports activities through Major League Gaming. The company has studios around the word with nearly 10,000 employees," Microsoft said. Bobby Kotick will continue to serve as CEO of Activision Blizzard, and he and his team will maintain their focus on driving efforts to further strengthen the company's culture and accelerate business growth. Once the deal closes, the Activision Blizzard business will report to Phil Spencer, CEO, Microsoft Gaming. "Gaming is the most dynamic and exciting category in entertainment across all platforms today and will play a key role in the development of metaverse platforms. We're investing deeply in world-class content, community and the cloud to usher in a new era of gaming that puts players and creators first and makes gaming safe, inclusive and accessible to all," said Satya Nadella, chairman and CEO, Microsoft.

08:34 EST Codex DNA showcases potential of SOLA EDS approach - Codex DNA announced that its R&D team has used the company's proprietary short oligo ligation assembly, SOLA, enzymatic DNA synthesis, EDS, technology to successfully construct the hemagglutinin and neuraminidase genes from the influenza A virus genome. SOLA EDS technology will be integrated into Codex DNA's upcoming BioXp Oligo Printer and BioXp Digital-to-Biological Converter systems, providing customers with an end-to-end solution for their life science research and synthetic biology needs. "We believe enzymatic DNA synthesis advances will ultimately propel the field of synthetic biology forward by enabling decentralized and automated DNA, mRNA, and protein writing solutions for multiple workflows, including the discovery and manufacturing of biologics and vaccines," said Todd R. Nelson, PhD, CEO of Codex DNA. "By incorporating SOLA EDS into future benchtop instruments, we will allow our customers to print DNA, RNA, and proteins just like a desktop printer prints documents." Because SOLA combines purified and sequence-verified DNA blocks to synthesize oligos, it has the potential to be faster, more accurate, and higher-throughput than existing EDS technologies. In addition, these DNA building blocks can be manufactured in large quantities and used extensively before replenishment, reducing the cost of DNA synthesis.

08:32 EST Vallon Pharmaceuticals presents new data from adult simulant abuse survey - Vallon Pharmaceuticals announced that new data from its recently-sponsored survey of stimulant abuse patterns in adults was presented at the APSARD 2022 Annual Conference, held virtually January 14-16, 2022. The poster titled, "Characteristics and Behaviors of Recreational Prescription Stimulant Users: Findings from an mTurk online survey," outlined additional results from a large survey, led by researchers at the University of Kentucky, of nearly 500 people who misuse or abuse prescription stimulants. David Baker, Chief Executive Officer of Vallon, commented, "With the misuse and abuse of prescription stimulants continuing to climb, the unmet need for abuse-deterrent formulations, and the potential of our platform technology, continues to grow. As we near the topline data readout for our lead program, ADAIR, we are pleased to report additional insights on the characteristics and behaviors of stimulant users, especially those who snort prescription stimulants. We look forward to reporting topline data from our pivotal SEAL study in the near term and, importantly, providing a potential solution to the help address the growing stimulant abuse problem."

08:31 EST Homeowners of America introduces services in Montana - Homeowners of America announced the launch of service in Montana.

08:29 EST Microsoft acquire Activision Blizzard for $95.00 per share in cash - Microsoft (MSFT) announced plans to acquire Activision Blizzard (ATVI), which it calls "a leader in game development and interactive entertainment content publisher," stating that this acquisition will "accelerate the growth in Microsoft's gaming business across mobile, PC, console and cloud and will provide building blocks for the metaverse." Microsoft will acquire Activision Blizzard for $95.00 per share, in an all-cash transaction valued at $68.7B, inclusive of Activision Blizzard's net cash. "When the transaction closes, Microsoft will become the world's third-largest gaming company by revenue, behind Tencent and Sony. The planned acquisition includes iconic franchises from the Activision, Blizzard and King studios like 'Warcraft,' 'Diablo,' 'Overwatch,' 'Call of Duty' and 'Candy Crush,' in addition to global eSports activities through Major League Gaming. The company has studios around the word with nearly 10,000 employees," Microsoft said. Bobby Kotick will continue to serve as CEO of Activision Blizzard, and he and his team will maintain their focus on driving efforts to further strengthen the company's culture and accelerate business growth. Once the deal closes, the Activision Blizzard business will report to Phil Spencer, CEO, Microsoft Gaming. "Gaming is the most dynamic and exciting category in entertainment across all platforms today and will play a key role in the development of metaverse platforms. We're investing deeply in world-class content, community and the cloud to usher in a new era of gaming that puts players and creators first and makes gaming safe, inclusive and accessible to all," said Satya Nadella, chairman and CEO, Microsoft.

08:27 EST Exela Technologies expands relationship with large technology provider - Exela Technologies announced it has augmented an existing relationship with a large technology services provider for several Medicaid programs across the nation. The initial component of the expansion is valued in excess of $2.5M. This deployment builds on a 25-year partnership and leverages Exela's PCH Global platform. PCH Global deployment will connect providers, Medicaid agencies and members to help drive clean claims and significantly reduce the need for retrospective collections. "Exela continues to invest in increasing PCH Global's capabilities to provide a cloud hosted solution with one of the best edit resolutions for healthcare claims," the company said. This extension of deployment marks another milestone in the value proposition of the PCH Global platform to digitally connect members, providers and insurance companies to enable clean claims, payment transparency and digital appeals.

08:25 EST EQRx announces two Lancet Oncology publications of Phase 3 results - EQRx announced that data from its partner CStone Pharmaceuticals' two pivotal Phase 3 studies of the anti-PD-L1 monoclonal antibody sugemalimab for the treatment of non-small cell lung cancer, NSCLC, GEMSTONE-301 and GEMSTONE-302, were published in The Lancet Oncology. The publications were accompanied by a comment article. Results from GEMSTONE-301 reported in The Lancet Oncology are as follows: Sugemalimab as consolidation therapy demonstrated a statistically significant and clinically meaningful improvement in PFS vs. placebo, as assessed by blinded independent central review at a prespecified interim analysis. Median PFS was 9.0 months vs. 5.8 months. Clinical benefit was observed in patients who received either concurrent or sequential chemoradiotherapy prior to treatment with sugemalimab compared to placebo. Overall survival data were immature at the time of the analysis, but an encouraging trend for a survival benefit with sugemalimab vs. placebo was observed, with follow-up of patients ongoing. Sugemalimab was generally well-tolerated, with no new safety signals observed. In the sugemalimab group, 9% of patients experienced grade 3 or 4 treatment-emergent adverse events related to study treatment. In the placebo group, 6% experienced grade 3 or 4 TEAEs related to study treatment. Results of the final PFS analysis from GEMSTONE-302, also reported in The Lancet Oncology, are as follows: Sugemalimab plus platinum-based chemotherapy significantly prolonged PFS compared with placebo plus platinum-based chemotherapy. OS data were immature at the time of the final PFS analysis, but preliminary median OS was 22.8 months in the sugemalimab plus chemotherapy arm compared to 17.7 months in the placebo plus chemotherapy arm. Clinical benefit was observed across all subgroups, regardless of PD-L1 expression level or pathologic subtype of NSCLC. Sugemalimab was generally well-tolerated, with no new safety signals observed. 53.8% of patients in the sugemalimab group and 56.0% in the placebo group experienced treatment-related grade 3 or 4 TEAEs, with the most common events for both groups being neutrophil count decrease, white blood cell count decrease, anemia, platelet count decrease and neutropenia.

08:22 EST Affiliated Managers, Leda Braga increase investment in Systematica - Affiliated Managers Group and Systematica Investments announced that AMG and Leda Braga, Founder and Chief Executive Officer of Systematica, have jointly acquired the remaining minority equity interest in Systematica previously owned by a third-party investor. Following the transaction, Braga holds an increased majority ownership position, and AMG holds a substantial minority interest in the firm. "We are very pleased to further enhance our partnership with Systematica, one of the leading independent technology-driven investment managers globally," said Jay Horgen, President and Chief Executive Officer of AMG. "Leda and the Systematica management team have been terrific partners over the years, and have built a renowned investment firm that has only extended its long-term track record of generating strong, differentiated returns for clients. Our increased investment reflects our confidence in Leda's leadership and in the firm's forward prospects." The terms of the transaction were not disclosed.

08:19 EST Enphase Energy expands battery storage in Illinois - Enphase Energy announced that Enphase installers in Illinois have seen increased deployments of Enphase Energy Systems, powered by IQ Microinverters and IQ Batteries, as Illinois continues its commitment to clean energy. Illinois recently approved the Climate and Equitable Jobs Act, which includes a commitment to 100% clean energy by 2050 and funding to support renewable energy and energy storage deployments. Enphase delivers a safer solar-plus-battery solution which does not expose installers or homeowners to high-voltage DC. The Enphase IQ Battery features Lithium Iron Phosphate battery chemistry, which provides a long cycle life and safer operation through excellent thermal stability. "We are encouraged by Illinois' commitment to accelerating the clean energy transition," said Dave Ranhoff, chief commercial officer at Enphase Energy. "As the state works to incentivize residential solar and energy storage deployments, Enphase is pleased to have partnered with such an outstanding group of world-class installers who are poised to meet this growing demand."

08:18 EST Kymera Therapeutics appoints John Maraganore to board of directors - Kymera Therapeutics (KYMR) announced the appointment of John Maraganore, Ph.D. to its Board of Directors. Dr. Maraganore joins Kymera's Board after having led Alnylam Pharmaceuticals (ALNY) as founding CEO and Director.

08:18 EST electroCore 'excited' about long-term prospects - The company said, "We continue to be excited about the long-term prospects of our Company and would like to share some of the reasons for our optimism. We are investing in marketing initiatives that we believe will make our gammaCore therapy available directly to consumers through multiple channels at a very compelling price. Among these channels are our newly launched e-commerce storefronts in the United Kingdom and the United States. Headache patients can now access gammaCore therapy simply by going to our web site and filling out a short questionnaire. The questionnaire is reviewed by a Health Care Professional who can write prescriptions for the therapy and moved into a shopping cart on our e-commerce storefront. After the gammaCore product is received by the patient, our customer experience team provides a variety of hands-on tools for patient training and support. Our team then stays in regular contact with the patient, providing further support during the course of the therapy and reminders about refill opportunities. In parallel with our online stores, we have launched our gConcierge and gCDirect programs for a growing number of physician prescribers in the US. These new programs allow physicians to offer their patients the opportunity to purchase gammaCore therapy directly through their offices or directly from us. We have broadened our call points from the traditional neurology headache specialists to include a wider range of medical providers who manage patients' headache conditions, including those in primary care, women's health, pain management, functional and integrative medicine, as well as chiropractors and Doctor of Pharmacy. In total, we have had approximately 200 prescribers write scripts through the gConcierge and gCDirect programs, all of whom have patients that can be supported by our in-house customer experience team. With the early growth and promise of success among these newly established, streamlined consumer access initiatives, we are planning to aggressively ramp up our spending on Direct-to-Consumer advertising and other promotional activities. Our goal is to drive consumer awareness and funnel that interest to our e-commerce stores and provider partners. In our legacy business channels, we have continued to grow our Department of Veterans Affairs and Department of Defense business in the United States, our National Health Service business in the United Kingdom, and our distributor relationships around the world. We plan to continue to invest in growth from these channels as we move through 2022, strengthened by our Direct-to-Consumer initiatives and advertising spend. While we continue to work towards expanding commercial insurance coverage for gammaCore in the United States, we recognize the barrier high deductible plans represent for many Americans and anticipate they will benefit significantly from our newly launched cash pay programs, even when coverage is available. Looking beyond primary headache, we anticipate reporting on our multiple clinical programs over the course of 2022. Ongoing trials continue to be conducted with our gammaCore therapy in secondary headache, traumatic brain injury, post traumatic stress disorder, stroke, opioid use disorder, Parkinson's, postoperative ileus, and other potential indications. We anticipate many of these programs will generate results that can support expanded labels and additional uses for gammaCore nVNS therapy, and support potentially expanded total addressable markets for our therapy. We believe nVNS therapy will be highly differentiated in conditions like concussion, PTSD, stroke, and opioid use disorder where there are few effective therapies currently. Finally, as we expand our commercial initiatives, we are also looking beyond organic growth opportunities and exploring ways to accelerate our growth through acquisitions that enhance and leverage the distribution channels we are developing. We have also continued to expand our intellectual property portfolio, especially in digital health and smartphone-integrated and smartphone-connected non-invasive therapy, which may provide us with opportunities to leverage our patents. We believe our intellectual property will be the foundation of next generation neuromodulation devices in the market, including our own nVNS devices. We look forward to enabling health care providers in their use of Remote Patient Monitoring and Remote Therapeutic Monitoring, which have been identified as critical areas for practice revenue growth in the future."

08:16 EST VBL Therapeutics appoints Matthew Trudeau as CCO - VBL Therapeutics (VBLT) announced the appointment of Matthew Trudeau to the newly created position of Chief Commercial Officer, CCO. Trudeau will be responsible for all commercialization activity for ofranergene obadenovec. His appointment further advances VBL's strategic plan to become a commercial organization and establish operations in the United States. Matthew Trudeau brings over 25 years of U.S. and international experience. From 2016 to 2021, he held positions of increasing responsibility at bluebird bio (BLUE), culminating in his appointment as Head of the U.S. business team.

08:15 EST Amdocs joins consortium to advance open RAN deployment - Amdocs announced that it is part of a consortium that has secured UK Government funding in an initiative designed to accelerate Open RAN deployment in the UK and globally. The "Accelerating RAN Intelligence in 5G," ARI-5G, consortium is one of several winning bids to receive funding from the UK's Department for Digital, Culture, Media and Sport, DCMS, through its Future RAN, FRANC, competition. Led by the Telecom Infra Project, ARI-5G will validate use cases for open and disaggregated solutions with innovations in 5G power consumption, energy efficiency, and spectrum management - accelerating successful and scalable commercialization over an initial 18-month period. The consortium will implement, test and demonstrate a standards-based RAN Intelligent Controller platform with specific applications. The project will result in proven RAN automation use cases that can be deployed in both third party and open-source RICs, providing real-world validation in a 5G SA network.

08:14 EST I-MAB says first patient dosed in China Phase 2 lemzoparlimab/toripalimab trial - I-Mab announced that the first patient has been dosed in its China phase 2 trial of lemzoparlimab in combination with the PD-1 antibody toripalimab in patients with advanced solid tumors. The phase 2 study is designed as a basket trial and could potentially lead to a registrational trial in China.

08:13 EST SciSparc secures two sites for Phase IIb Tourette Syndrome clinical trial - SciSparc has entered into an agreement with two clinical sites: Hannover Medical School in Hannover, Germany, and Tel-Aviv Sourasky Medical School, in Tel-Aviv, Israel, to further its Phase IIb clinical study for SCI-110, the company's proprietary drug candidate, for patients suffering from Tourette syndrome. The trial will be conducted at the two sites. The trial will be a randomized, double-blind, placebo-controlled, cross-over study to evaluate the efficacy, safety and tolerability of daily oral SCI-110 as compared to placebo, in treating adults age 18 to 65, with Tourette syndrome. Patients will be evaluated in a cross-over design, with each subject randomized to receive either SCI-110 or placebo via oral administration. Tourette syndrome is a neurological disorder characterized by involuntary movements and vocalizations called tics and is estimated to affect approximately 1% of the world's population.

08:13 EST CryoLife renaming, rebranding itself to 'Artivion' - CryoLife (CRY) announced that it was renaming and rebranding itself to Artivion (AORT), effective immediately. Derived from the words "aorta", "innovation", and "vision", the company's new name and brand reflect its evolution to focus on providing innovative technologies to surgeons who treat patients with aortic disease. In conjunction with these changes, effective January 24, the company will also change its ticker symbol on the New York Stock Exchange to "AORT" from "CRY."

08:12 EST Arqit Quantum announces partnership with AUCloud - Arqit Quantum welcomes Sovereign Cloud Australia as the latest local service provider to join the Federated Quantum System for deployment in Australia in partnership with the Australian Government. AUCloud is an Infrastructure-as-a-Service provider selling high security sovereign cloud services to the Australian Government, Defence, Intelligence, and Critical National Industry communities. By addressing urgent threats to existing cybersecurity infrastructure and creating the foundations for critical future capabilities, Arqit's partnership with AUCloud will deliver an immediate capability to Australian customers in the Defence, Government, Critical National Infrastructure and Enterprise sectors, including Financial Services. The relationship will also provide further opportunities for Australian industrial participation in space, cyber and quantum technologies. Arqit Founder, Chairman and CEO, David Williams, added: "We are delighted to support the Australian, UK and US alliance for joint defence investment and innovation. The world needs stronger, simpler encryption, and it is important that allied countries work together to share the benefit of Arqit's globally unique, transformational quantum safe encryption. We look forward to deepening our partnership with Australian industry in this effort."

08:10 EST Ocular Therapeutix announces first patient dosed in Dextenza trial in China - Ocular Therapeutix announced that AffaMed Therapeutics dosed its first patient in a real-world setting study being conducted in China evaluating the safety and efficacy of Dextenza for the treatment of ocular inflammation and pain post-cataract surgery. In 2020, Ocular entered into a licensing agreement with AffaMed Therapeutics for the development and commercialization of Dextenza in Greater China, South Korea, and the ASEAN markets. Dextenza is currently approved in the U.S. for the treatment of ocular inflammation and pain following ophthalmic surgery and for the treatment of ocular itching associated with allergic conjunctivitis. Under the terms of the agreement with AffaMed, Ocular Therapeutix has been paid an upfront payment of $12M and is eligible to receive development, regulatory and commercial milestone payments and clinical development support payments of up to an additional $91M in the aggregate, as well as royalties from future product sales. Royalties are tiered and will range from the low teens to low twenty percent range. In return, Ocular Therapeutix has agreed to grant AffaMed exclusive rights to develop and commercialize Dextenza for the treatment of post-surgical inflammation and pain following ophthalmic surgery and ocular itching in patients with allergic conjunctivitis, and OTX-TIC for the reduction of intraocular pressure in patients with primary open-angle glaucoma or ocular hypertension in Greater China, which includes mainland China, Hong Kong, Macau, and Taiwan; South Korea; and the ASEAN Countries. Ocular Therapeutix retains the right to develop and commercialize Dextenza and OTX-TIC in all other global markets.

08:10 EST Uniti Group signs long-haul dark fiber agreement with internet provider - Uniti Group announced that it has signed a twenty-year contract with a large international internet provider, offering long-haul dark fiber connectivity to premier data centers in the Bay Area, Salt Lake City and Denver. This agreement provides scalable and secure transport over a 1,440 mile key route that connects the Bay Area to Denver. "This latest global customer contract proves Uniti is well-positioned to execute on our mission of providing the critical communications infrastructure needed to seamlessly connect the world. Our steady history of delivering secure and flexible long-haul transport options to our carrier and provider partners is further underscored by our ability to create customized solutions that support international business growth and success," said Thomas Vito, Vice President, Strategy & Business Development at Uniti. "Not only does this agreement support our nationwide fiber-rich network and collaborative approach as compelling differentiators, it also demonstrates our commitment to leveraging our fiber network to support increasing lease-up opportunities."

08:09 EST Exxon Mobil announces ambition for net zero greenhouse gas emissions by 2050 - ExxonMobil announced its ambition to achieve net zero greenhouse gas emissions for operated assets by 2050, backed by a comprehensive approach to develop detailed emission-reduction roadmaps for major facilities and assets. The net-zero aspiration applies to Scope 1 and Scope 2 greenhouse gas emissions and builds on ExxonMobil's 2030 emission-reduction plans, which include net-zero emissions for Permian Basin operations and ongoing investments in lower-emission solutions in which it has extensive experience, including carbon capture and storage, hydrogen and biofuels, the company said in a statement. "ExxonMobil is committed to playing a leading role in the energy transition, and Advancing Climate Solutions articulates our deliberate approach to helping society reach a lower-emissions future," said Darren Woods, chairman and CEO. "We are developing comprehensive roadmaps to reduce greenhouse gas emissions from our operated assets around the world, and where we are not the operator, we are working with our partners to achieve similar emission-reduction results." To help reach net zero for operated assets by 2050, the company has identified more than 150 potential steps and modifications that can be applied to assets in its upstream, downstream and chemical operations. Initial actions already underway prioritize energy efficiency measures, methane mitigation, equipment upgrades and the elimination of venting and routine flaring. Further high-impact reduction opportunities include power and steam co-generation and electrification of operations, using renewable or lower-emission power. The company expects to finalize detailed roadmaps that address approximately 90% of operations-related greenhouse gas emissions by the end of this year, and the remainder will be completed in 2023. Initial steps to achieve net zero by 2050 are included in the company's plans to invest more than $15B by 2027 on lower-emission initiatives.

08:09 EST CN Energy unit signs O&M agreement with HuaiNan JiaHe New Materials Co. - CN Energy Group announced that its subsidiary Hangzhou Forasen Technology Co., Ltd. signed an operation and management agreement with HuaiNan JiaHe New Materials Co., Ltd. and JiaHe's activated carbon subsidiary, NingGuo ZheWanZhenHua Activated Carbon Industry Co., LTD. Under the Agreement, the company will be fully responsible for the operation, production, sales and management of ZhenHua and receive a quarterly management fee. Founded in 1985, ZhenHua is focused on R&D and production, processing, marketing of activated carbon specially used as pharmaceutical excipients and food additives. The company has two very scarce qualifications in this industry to manufacture pharmaceutical excipients and food additives. The company currently employs more than 90 professionals on its 18,000 square meter campus.

08:08 EST Harsco increases focus on expanding SteelPhalt - Harsco Environmental announces it has increased its focus on expanding SteelPhalt as a world-leading asphalt company with unique solutions for every roadmaking challenge. This includes relaunching SteelPhalt's website making it faster and easier-to-use, featuring a new product selector designed to aid current and potential customers in decision-making when specifying materials for a project. Actions such as ordering and tracking will also be automated on the new site to lower customer time spent on administrative tasks. Through sustainable products that deliver high skid resistance and better durability, SteelPhalt makes high-performance asphalt to reduce the carbon footprint of road-laying by 40-percent. These trusted solutions aim to protect the planet and deliver durable roads for a more sustainable world. Today's announcement follows SteelPhalt's continued expansion in support of sustainable roadmaking. The Company recently announced the opening of two new asphalt plants located in Cardiff, Wales, and an additional plant at the existing Rotherham, England, facility, manufacture sustainable asphalt products using 95-percent recycled aggregates. With plans to open several facilities over the next three years outside of the U.K., the additional plants will offer Harsco another resource for handling slag from its steel mill customers while also responding to the ever-increasing demand to be more sustainable.

08:07 EST Moleculin Biotech announces updated safety data for Annamycin in Phase 1 trials - Moleculin Biotech reported that it has received an updated independent safety review of certain preliminary data for the first 30 patients in its three Phase 1 clinical trials with Annamycin targeting relapsed or refractory acute myeloid leukemia and the metastases of soft tissue sarcoma to the lungs, which concluded there was no evidence of cardiotoxicity. The review included analysis of ejection fraction, echo strain and certain troponin levels intended to assess potential for both acute and chronic heart damage. Additionally, the company reported evidence that Annamycin may have a substantially lower incidence of alopecia (hair loss) than currently prescribed anthracyclines such as doxorubicin. Although 65%-92% of patients treated with doxorubicin typically experience hair loss, the incidence to date in patients treated with Annamycin is less than 10%. Alopecia is considered an important factor in quality of life for many cancer patients. "Annamycin was designed to produce little to no cardiotoxicity, so we are pleased to see that this updated report continues to support that objective," commented Walter Klemp, Chairman and CEO of Moleculin. "This is a critical safety improvement in the field of anthracyclines since the risk of cardiotoxicity is the primary limitation in the use of currently prescribed anthracyclines. The apparent reduction in the incidence of hair loss is an added benefit that has the potential to significantly improve the quality of life for patients needing anthracycline therapy. We are also encouraged by the pace of recruitment for the STS Lung clinical trial and look forward to hopefully continuing the current pace of cohort updates. While the European AML trial has been slow in recruiting, we expect to announce an update regarding the next cohort in the first quarter of 2022."

08:06 EST WISeKey files patent application for NFTS minted on blockchains - WISeKey International Holding announced that it has filed a patent application that ensures the provenance, authenticity, persistence, and long-term value of NFTs that are minted on Blockchains using this method. During the minting process, this method allows to ensure that the NFT is not corrupted, incomplete, or ambiguous. The WISeSat.Space constellation is already enabling the direct connection of satellites to IoT devices for NFT authentication, completing the connection cycle from space to device through a secure telecommunication means. WISeSat.Space satellites launched last week are working correctly and communicating with VaultIC encrypted communications despite working in extremely low temperatures. During the testing phase, which will take 2-4 weeks, WISeKey will be working to activate the NFT, and then execute the launch of a prestigious art piece in mid-February. The space based NFT ecosystem assures personal and secure authentication capabilities through the global WISeSat.Space constellation developed in partnership with FOSSA Systems. This solution can be used in multiple industrial applications to: optimize productivity across industries through predictive maintenance on equipment and machinery, create truly smart homes with connected appliances, and provide critical communication between devices including autonomous vehicles, self-driving cars and trucks and smart homes.

08:04 EST Clarus appoints Greg Heichelbech as GM, Rhino Rack USA - Rhino Rack has appointed Greg Heichelbech to the new role of General Manager of Rhino Rack USA. Heichelbech has over 30 years leadership, operations, and sales and marketing experience working in the branded aftermarket, powersports and outdoor markets. He will be responsible for expanding the presence of Clarus' Rhino Rack and MAXTRAX brands in North America. He joins Rhino Rack from Motorsports Aftermarket Group.

08:03 EST Nikola, Proterra announce multi-year supply agreement - Nikola (NKLA) and Proterra (PTRA) announced a strategic, multi-year supply agreement to power Nikola zero-emission semi-trucks with Proterra's industry-leading battery technology. Proterra product is expected to be incorporated in the Nikola Tre battery-electric vehicle and Tre fuel cell electric vehicle. The first Proterra Powered Nikola semi-trucks are expected to be produced in the fourth quarter of 2022, with Proterra delivering prototype systems to Nikola starting in the second quarter of 2022.

08:03 EST Lawrence County, South Dakota selects BIO-key's PortalGuard IAM platform - BIO-key announced Lawrence County, SD has selected its PortalGuard IAM platform, including WEB-key biometric authentication. PortalGuard will provide its staff with seamless, secure access to mission-critical county applications and data that meets its cyber security and insurance compliance requirements.

08:02 EST Dyne Therapeutics announces FDA clinical hold on DYNE-251 IND application - Dyne Therapeutics announced that the U.S. Food and Drug Administration has placed on clinical hold its Investigational New Drug application to initiate a clinical trial of DYNE-251 in patients with Duchenne muscular dystrophy amenable to skipping exon 51. Dyne received a clinical hold letter from the FDA on Friday, January 14, 2022 requesting additional clinical and non-clinical information for DYNE-251. The Company expects to submit to the FDA its response with data from existing and ongoing studies in the second quarter of 2022, and if satisfactory to the FDA, to be dosing patients in a Phase 1/2 multiple ascending dose clinical trial of DYNE-251 by mid-2022 in accordance with its current guidance. Dyne will work closely with the FDA to resolve the clinical hold as promptly as possible. As previously announced, the Company expects to submit an IND for DYNE-101 in myotonic dystrophy type 1 during the first quarter of 2022 and to be dosing patients in a planned MAD clinical trial by mid-2022.

07:57 EST Science 37, Worldwide Clinical Trials partner to advance agile clinical trials - Worldwide Clinical Trials and Science 37 Holdings announced a collaboration to enable enhanced decentralized clinical trial delivery in which patient visits for the provision of healthcare or trial assessments and laboratory tests are localized in the patient's community. With this new partnership, Worldwide will leverage Science 37's Operating System-bringing biopharmaceutical sponsors an end-to-end technology platform and specialized networks solutions for faster and more patient-centric clinical trial execution. As sponsors continue to explore ways to drive accelerated study timelines and bring trials closer to patients, use of decentralized techniques and approaches are leading to increased agile clinical trial designs. Enabled by technology, agile clinical trials can alleviate patient burdens-helping drive efficiency, reduce costs, and increase patient participation by incorporating the best elements of traditional and decentralized approaches. Through this partnership, Worldwide Clinical Trials becomes part of the Science 37 CRO Certified network, designed to empower CROs with access, training, and commercial support to successfully deliver decentralized clinical studies at scale.

07:45 EST Alexco Resource's resource estimate for Bermingham deposit increases by 70% - Alexco Resource reports an updated and expanded mineral resource estimate for the company's Bermingham deposit, located within the Keno Hill Silver District in Canada's Yukon Territory. As a result of exploration work conducted during the period 2019 through 2021, including the recently completed 17,742 m directional drilling program, the Bermingham indicated mineral resource estimate has expanded from 33.0 M ounces to 47.2M ounces of contained silver at an average grade of 939 g/t Ag. The inferred mineral resource estimate has increased from 11.7 M ounces to 19.9 M ounces of contained Ag at an average grade of 735 g/t Ag. Including the expanded silver mineral resource at Bermingham, the total indicated mineral resource estimate for the company's two primary mining centers in the District, the Bermingham and Flame & Moth deposits, increased by 24% from 59.8 M ounces to 74.1 M ounces of contained silver. As a result of these changes, Alexco is currently re-evaluating the life of mine plan for both deposits with a view to potentially expand the combined estimated 33.8 M ounce silver mineral reserve.

07:39 EST Profound Medical announces first patients treated in CAPTAIN trial - Profound Medical announced that the first patients have been treated in the Level 1 'CAPTAIN' trial. CAPTAIN is a prospective trial of 201 patients aimed at comparing the safety and efficacy of the TULSA procedure with radical prostatectomy in men with organ-confined, intermediate-risk, Gleason Score 7 prostate cancer. The primary safety endpoint is the proportion of patients who preserve both erectile potency and urinary continence at one year after treatment. The primary efficacy endpoint is the proportion of patients who are free from any additional treatment for prostate cancer by three years after treatment. Secondary endpoints include comparison of rates of complications, cost effectiveness, and timing of the return to baseline activity. Long-term follow-up will be gathered for up to 10 years after treatment. "CAPTAIN is a post-market study intended to support coverage by payors," said Arun Menawat, Profound's CEO and Chairman. "Notably, this will be the first Level 1 study ever conducted comparing an emerging technology head-to-head with RP in men with prostate cancer. So, if successful, in addition to helping advance our reimbursement strategy, we believe the data generated from CAPTAIN has the potential to drive much broader awareness and adoption of TULSA-PRO."

07:37 EST OverActive Media appoints Matt McGlynn as VP, marketing and brand - OverActive Media announced the hiring of Matt McGlynn to its leadership team in Toronto. McGlynn leaves his prior role as Vice President of Brand at Royal Bank of Canadato join OverActive as Vice President of Marketing and Brand.

07:36 EST Enovix completes redemption of public warrants - Enovix announced the completion of the redemption of all of its outstanding public warrants. On December 7, 2021, Enovix issued a press release stating that, pursuant to the terms of the warrant agreement, it would redeem all of the public warrants that remained unexercised immediately after 5:00 p.m., New York City time, on January 7, 2022 for a redemption price of $0.01 per warrant. The redemption was triggered because the last sales price of Enovix's common stock was at least $18.00 per share on each of 20 trading days within the 30 trading-day period that ended December 2, 2021. Of the 11,499,991 public warrants that were outstanding as of the date Enovix announced the redemption of its public warrants on December 7, 2021, 11,304,351 were exercised, representing approximately 98.3% of the public warrants. Enovix redeemed 195,640 unexercised public warrants. Total cash proceeds generated from the public warrant exercises were approximately $130.0 million. As of this date, no public warrants remain outstanding. In connection with the redemption, the public warrants stopped trading on the Nasdaq Capital Market and were delisted, with the trading halt announced after close of market on Friday, January 7, 2022. The redemption had no effect on the trading of Enovix's common stock, which continues to trade on the Nasdaq Capital Market under the symbol "ENVX."

07:35 EST Marimed to acquire Green Growth Group, terms not disclosed - MariMed announced it signed a definitive agreement to acquire Green Growth Groupm holder of a provisional Cannabis Craft License in Illinois. The transaction is subject to customary closing conditions and regulatory approvals. Terms of the deal were not disclosed. This transaction will enable MariMed to add cultivation, manufacturing, and distribution to its existing retail cannabis operations in the state. MariMed will bring its full product portfolio of brands, genetics, and products to one of the top cannabis markets in the United States. For this Craft License, the Company will acquire a building to develop up to 14,000 square feet of canopy for cultivation, build an extraction lab to produce concentrates, and build a production kitchen for the manufacture of edibles and other derivative products. A Transportation License also being acquired will enable the Company to wholesale its products throughout Illinois. The Company intends to manufacture and distribute in Illinois its proprietary brands and products, including its Betty's Eddies fruit chews, which was one of the top-selling edibles in the state until 2019 through a third-party licensing agreement, its award-winning Nature's Heritage flower and concentrates, its Bubby's Baked soft and chewy baked edibles, and more.

07:33 EST Orgenesis, John Hopkins University create new POCare Center - Orgenesis and The Johns Hopkins University announce the next phase of their collaboration. This new phase involves construction of a cell and gene therapy processing facility for point of care treatment of patients at Johns Hopkins which is planned to start in Q2 2022 and is expected to be operational in Q2 of 2023. Construction of the new POCare Center, also known as the Maryland Center for Cell Therapy Manufacturing, has been funded in part by a $5M grant from the State of Maryland. The new facility has been designed to meet U.S. Food and Drug Administration standards and provides Johns Hopkins clinicians and researchers with a "more streamlined path to treat patients and take promising and novel treatments from the lab to patient trials," the company said. In addition, the establishment of the new POCare Center will enable rapid scale up of additional processing capacity through connecting/servicing Orgenesis Mobile Processing Units and Labs. OMPULs shorten the implementation time of new capacity from 18-24 months to 3-6 months. Each POCare Center can service multiple OMPULS. The first OMPUL in Maryland is expected to deploy 2H of 2022. "Orgenesis continues to develop and extend key partnerships within its international POCare Network. These international partnerships are now experiencing significant investment and construction across the globe to build on the achievements within the Network, as illustrated by our expanded collaboration with Johns Hopkins," said Vered Caplan, CEO, Orgenesis. "We are honored to work with Johns Hopkins, America's first research university and home to nine world-class academic divisions working together in one university. The POC Center at Johns Hopkins will help propel the development of therapies targeting a range of conditions that directly affect the lives of millions of patients."

07:33 EST EbixCash Global Services secured seven contracts in Q4 - EbixCash Private announced that its subsidiary EbixCash Global Services has secured seven new contracts in the fourth quarter of the year 2021. Reviewing its performance in the year 2021 as compared to 2020, the EbixCash Global Services Division announced a number of metrics to gauge its success - As of 31st December 2021, its employee count had grown to 2,850 from 810 in September 2020; 28 new clients were secured in the year 2021, with seven new clients still in the process of being onboarded; Year over year revenue growth reported in 2021 was 54%; Today the Division is proudly associated with 78 leading clients. The Division successfully set up a 125,000 square feet Headquarters in Sector-80, Noida in 2021.

07:32 EST Osisko Mining announces results from drill program at Windfall project - Osisko Mining is pleased to provide new analytical results from the ongoing drill program at its 100% owned Windfall gold project located in the Abitibi greenstone belt, Urban Township, Eeyou Istchee James Bay, Quebec. Significant new analytical results that have not been included in the recently released mineral resource estimate and include 94 intercepts in 28 drill holes and 25 wedges. The infill intercepts are located inside defined January 2022 MRE blocks. The expansion intercepts are located outside the January 2022 MRE blocks and either expand MRE wireframes or are in a defined zone or corridor but do not yet correlate to a specific MRE wireframe. Osisko CEO John Burzynski commented: "Today's results serve as a reminder that Windfall continues to grow in size, underscored by some of these new wide high-grade hits as the deposit opens up in the heart of the Lynx system. By virtue of the current resource, Windfall is the largest high-grade million ounce plus deposit ever discovered in Quebec, and it has been steadily moving up the global list of top high-grade underground gold deposits. There is nothing quite like Windfall in Canada, or even globally." Selected high-grade intercepts include: 482 g/t Au over 5.7 metres and 380 g/t Au over 3.2 metres in OSK-W-21-1432-W10; 77.6 g/t Au over 17.3 metres in OSK-W-21-1949-W14; 124 g/t Au over 8.0 metres in OSK-W-21-2587-W2; 45.8 g/t Au over 11.0 metres and 143 g/t Au over 3.4 metres in WST-21-0707; 87.9 g/t Au over 3.2 metres in OSK-W-21-2465-W5; 83.0 g/t Au over 3.0 metres in WST-21-0895A, 37.0 g/t Au over 6.4 metres in OSK-W-21-2613 and 28.1 g/t Au over 6.0 metres in OSK-W-21-2644.

07:30 EST Social Capital Suvretta Holdings Corporation III (Class A Stock) trading resumes

07:27 EST Social Capital Suvretta Holdings Corporation III (Class A Stock) trading halted, news pending

07:27 EST Eliem Therapeutics provides program updates, near term milestones - Eliem Therapeutics is providing program updates and announcing expected milestones. Program Updates and Anticipated Key Milestones: ETX-810 in chronic pain: ETX-810 is currently being evaluated in two Phase 2a clinical trials in subjects with diabetic peripheral neuropathic pain and lumbosacral radicular pain, commonly referred to as sciatica. ETX-810 in DPNP. Achieved full enrollment in the Phase 2a trial evaluating the efficacy and safety of ETX-810 in subjects with DPNP. The Company expects topline data in the first half of 2022. ETX-810 in LSRP. Enrollment is ongoing for the Phase 2a clinical trial evaluating the efficacy and safety of ETX-810 in subjects with LSRP. The Company expects enrollment to be completed in the first half of 2022 and now expects topline data in the second half of 2022. ETX-155 in depression and epilepsy: ETX-155 is a novel GABAA receptor positive allosteric modulator that Eliem plans to evaluate in subjects with major depressive disorder, perimenopausal depression, and epilepsy. ETX-155 in MDD and PMD. The Company expects to submit an IND application with the U.S. Food and Drug Administration in Q1 2022. Assuming FDA clearance to proceed, the Company expects to dose the first subjects in two randomized, placebo-controlled, Phase 2a proof-of-concept trials of ETX-155 in the first half of 2022 and expects topline data in the second half of 2023. ETX-155 in epilepsy. Enrollment is ongoing for the single-arm Phase 1b trial in subjects with photosensitive epilepsy, a single dose proof-of-concept study for epilepsy. The Company expects interim data in the first half of 2022. Kv7.2/3 channel opener program: The Company's preclinical program targets the Kv7.2/3 potassium channel, a target that has been shown to control neuronal excitability and that has clinical validation in pain and epilepsy. The Company plans to progress IND-enabling studies in 2022. Anxiolytic for generalized anxiety disorder: The Company is in early preclinical development of a novel, rapid-acting, non-sedating, non-addictive anxiolytic for the potential treatment of GAD. The Company is continuing the preclinical development of this program with the intent to provide a development plan update later in 2022.

07:26 EST Centerra Gold reports Q4 gold production 91,197 ounces - Centerra Gold reports 2021 fourth quarter and full-year production and 2022 production and cost guidance. 2021 Fourth Quarter and Annual Highlights: Gold production in the fourth quarter was 91,197 ounces including 59,529 ounces of gold produced by the Mount Milligan Mine and 31,668 ounces of gold produced by the Oksut Mine. Full year 2021 gold production was 308,141 ounces, at the upper end of guidance, including 196,438 ounces of gold produced by the Mount Milligan Mine and 111,703 ounces produced by the Oksut Mine. Copper production was 17.0 million pounds in the fourth quarter and 73.3 million pounds for the full year 2021, within the guidance range. 2021 Gold production costs per ounce is expected to be at the lower end of the guidance range of $600 to $650. 2021 All-in sustaining costs on a by-product basis per ounce is expected to be below the lower end of guidance range of $700 to $750. 2021 All-in costs on a by-product basis per ounce is expected to be below the lower end of guidance range of $850 to $900. 2021 Cash provided by operating activities is expected to be at the upper end of the guidance range of $200 to $250 million. 2021 Free cash flow is expected to be at the upper end of the guidance range of $125 to $175 million. 2021 Oksut related income tax guidance has been revised to an expected current tax expense range of $35 to $45 million.

07:25 EST Qiwi launches new website for investors - QIWI announced the launch of the new website for investors. The company said, "We are happy to announce that our website for investors was updated. We encourage you to visit it at the same link - https://investor.qiwi.com/. The new website received a modern and refreshing design in accordance with QIWI brand book guidelines. We have reviewed the structure, added several features describing our products & services, introduced new tools for investors and improved navigation."

07:25 EST Transocean to drill injection well, sidetrack for Northern Lights Project - Transocean (RIG) announced that, later this year as part of its current drilling contract with Equinor (EQNR), the Transocean Enabler will drill one carbon injection well and a sidetrack for another carbon injection well drilled early 2020 in support of the Northern Lights Carbon Capture Storage Project, a joint venture created by Equinor, Shell (RDS.A;RDS.B) and TotalEnergies (TTE). The project sets out to mitigate emissions and remove carbon dioxide from the atmosphere by creating the first cross-border, open-source carbon dioxide transport and storage infrastructure network in the European Union. "We are proud to participate in this important carbon capture and storage project in support of the EU's energy policy and climate objectives," said Janelle Daniel, Transocean's Vice President of Human Resources, Sustainability and Communications. "Beyond our core business of drilling ultra-deepwater and harsh environment wells, this is an excellent example of how we can further leverage our rigs and core competencies in support of renewable and alternative energy projects in offshore markets across the globe."

07:22 EST Amryt Pharma announces new patents for Oleogel-S10 - Amryt announces an update regarding the patents for its lead development candidate, Oleogel-S10. Oleogel-S10: The United States Patent and Trademark Office, USPTO, has issued to Amryt a notice of allowance for US Patent Application No. 17/393,171 'Betulin-Containing Birch Bark Extracts and their Formulation' with claims covering the Oleogel-S10 formulation. If Oleogel-S10 is approved by the FDA, the resulting patent will be listable in the Approved Drug Products with Therapeutic Equivalence Evaluations, published by the United States Food and Drug Administration and this patent will expire in January 2039. Together with four previously granted patents, if Oleogel-S10 is approved, Amryt will have 5 Orange Book-listed patents for Oleogel-S10 with patent protection through January 2039, without patent term extension. Dr Joe Wiley, CEO of Amryt Pharma, commented: "We are always working to develop and extend our IP portfolio and today's news further illustrates the robust IP protection enjoyed by our lead development asset, Oleogel-S10. Oleogel-S10 is a potential treatment for the cutaneous manifestations of Junctional and Dystrophic Epidermolysis Bullosa, a rare and distressing genetic skin disorder affecting young children and adults for which there is currently no approved treatment ."

07:19 EST Leyden Labs licenses pan-influenza antibody from Janssen - Leyden Laboratories announces the development of an intranasal spray protecting against influenza A and influenza B based on the human monoclonal antibody CR9114. Leyden Labs has entered into an exclusive licensing agreement with Janssen Pharmaceuticals to develop and commercialize CR9114 for mucosal administration. CR9114 is a human monoclonal antibody that protects against both influenza A and B in preclinical models. With the exclusive license to mucosal administration of CR9114, Leyden Labs is developing easy-to-use products that provide immediate protection against contracting and spreading multiple strains of influenza. This supports Leyden Labs' mission to optimize mucosal protection against entire viral families to prevent future pandemics. Under the terms of the licensing agreement, Janssen will provide Leyden Labs with a worldwide, exclusive license to develop and commercialize CR9114 for mucosal administration. Janssen will receive an upfront payment and is eligible to receive development and sales-based milestone payments and tiered royalties on potential sales. The agreement was facilitated by Johnson & Johnson Innovation.

07:18 EST Hain Celestial CFO Idrovo resigns for another opportunity, appoints Bellairs - The Hain Celestial Group announced the appointment of Chris Bellairs to the role of Executive Vice President and Chief Financial Officer, CFO, effective February 4, 2022. Bellairs will succeed Hain Celestial's current Executive Vice President and Chief Financial Officer, Javier Idrovo, who has announced his intention to resign for another opportunity. Idrovo will continue to serve as Chief Financial Officer until February 4, 2022, to assist with the transition of his responsibilities and to participate in the Company's upcoming conference call to discuss its second quarter fiscal year 2022 financial results. Prior to joining Hain Celestial, Bellairs served as the Chief Financial Officer of Stone Brewing, a California-based craft brewery with nationwide and international distribution.

07:16 EST Gold Standard Ventures announces results from eight RC holes at Pinion SB Zones - Gold Standard Ventures announced positive drill results from eight reverse circulation, RC, drill holes at the Pinion SB Zone as part of its 2021 Exploration and Development Program. The SB Zone is the contiguous southeast extension of the Pinion deposit. Jason Attew, President and CEO, commented, "We are very encouraged by the 2021 drilling results at the SB Zone. We are intersecting mineralization closer to surface than previously estimated and the target remains open to the south and east. We look forward to continuing to explore this target in 2022 with the goal of adding to the existing Pinion mineral resource by year-end."

07:15 EST ProKidney to become public through Social Capital Suvretta combination - ProKidney has entered into a definitive agreement to become a publicly traded company via a business combination with Social Capital Suvretta Holdings Corp. III (DNAC), a special purpose acquisition company. The transaction is expected to deliver up to $825M in gross cash proceeds, including the contribution of up to $250M of cash held in SCS's trust account, assuming no redemptions by SCS public shareholders, and a fully committed PIPE of $575M at $10 per share. These proceeds will be primarily used to fund React's Phase 3 development program, accelerate ProKidney's manufacturing buildout, and ultimately prepare for the global commercial launch of React. The PIPE is led by a $125M contribution from Social Capital, with an additional $50M from ProKidney's existing investors, approximately $30M from Suvretta Capital's Averill strategy with the remaining $370M coming from institutional investors and family offices. Existing ProKidney equity holders will roll 100% of their equity into the combined company and will be eligible to receive up to 17.5M additional SCS shares pursuant to an earnout based on ProKidney's future stock performance. Existing ProKidney shareholders and management have also committed to lock up 50% of their equity interests until the earlier of five years or regulatory market authorization, including full or conditional authorization, to market its lead product candidate, React, subject to certain customary exceptions. Upon closing of the transaction, the combined company will trade on the Nasdaq under the symbol (PROK). The transaction, which has been approved by the boards of directors of both SCS and ProKidney and ProKidney's equity holders, is expected to close in the third quarter of 2022 and is subject to approval by SCS's shareholders and other customary closing conditions.

07:13 EST Surgalign receives FDA clearance for HOLO Portal System - Surgalign announced that it has received U.S. Food & Drug Administration, FDA, 510(k) clearance for its HOLO Portal surgical guidance system for use within lumbar spine procedures. The HOLO Portal system is an artificial intelligence-driven augmented reality, AR, guidance system for spine and the first clinical application of Surgalign's HOLOTM AI digital health platform. "Receiving the initial clearance for the HOLO Portal system is a significant milestone and represents a critical step toward building the foundation of the digital surgery of the future. This system is designed to improve patient outcomes by delivering intelligent solutions to our customers, and we believe it is truly revolutionary," said Terry Rich, Surgalign's president and chief executive officer. "With clearance in hand for our guidance application, our near-term focus is getting the platform into the hands of surgeons as we work towards a market release. While the current capabilities of the HOLO Portal system have the potential to offer a quantum leap in the way surgical procedures are performed, we have a much larger vision for our HOLO AI digital health platform across a variety of healthcare specialties and throughout the care continuum."

07:12 EST Marqeta announces Suni Lobo as Chief Human Resources Officer - Marqeta announced the addition of Chief Human Resources Officer, Sunaina, Suni, Lobo as a key member of its executive team. Suni will be responsible for leading all areas of Marqeta's People, Places and Culture function globally. "Suni brings decades of experience leading best-in-class People teams to Marqeta. She has led transformative growth for global teams, focusing on building innovative and inclusive cultures and will be an invaluable asset to Marqeta and our growth," said Jason Gardner, Founder and CEO of Marqeta. "As we continue to mature as a company, Suni will have the skillset and leadership experience required to build, retain and grow an exceptional team and implement people-first processes that support our strong company culture."

07:11 EST Clene's CNM-ZnAg completes 50% patient enrollment in COVID-19 trial - Clene along with its subsidiaries "Clene" and its wholly owned subsidiary Clene Nanomedicine announced it has enrolled more than 50% of the approximately 276 planned participants for its Phase 2 multicenter, randomized, double-blind, placebo-controlled study assessing the efficacy and safety of CNM-ZnAg in acutely symptomatic, non-hospitalized COVID-19 patients in Brazil. CNM-ZnAg is a proprietary zinc-silver ionic solution that has demonstrated both antiviral and antibacterial activity. Study participants are randomized 1:1:2 to receive either a low dose of CNM-ZnAg, a high dose of CNM-ZnAg or placebo in addition to standard supportive care. The primary endpoint of the study is the prevention of hospitalization up to day 28, with a key secondary endpoint assessing time to complete symptom resolution. Topline results are expected in 1H 2022.

07:10 EST Xeris Biopharma reports additional $30M from capital raise on balance sheet - Xeris Biopharma Holdings announced a business update and reaffirmed its 2021 pro forma net sales and year-end cash balance guidance. "We are proud to have ended 2021 on a strong note with continued growth of Gvoke and Keveyis, delivering net sales at the upper end of our guidance range, over $100M of cash, cash equivalents, and investments on the balance sheet, and the approval of our third commercial product, Recorlev. 2022 is off to a good start with an additional $30 million from the recent capital raise on our balance sheet and the near-term launch of Recorlev," said Paul R. Edick, Chairman and CEO of Xeris Biopharma. "Since the launch of Gvoke, we have persistently worked to make Gvoke accessible for as many people with diabetes as possible. There are over 6.8M people with diabetes on insulin at risk of a severe hypoglycemic event, and we think every one of them should have access to a ready-to-use product such as Gvoke. We are very pleased that a growing number of Medicaid lives now have unrestricted access to Gvoke," said Mr. Edick. These estimated financial results are preliminary and subject to further review by the Company and its external auditors. Xeris will report fourth quarter and full year 2021 actual financial results in March 2022. The Company also anticipates giving guidance for full-year 2022 net sales and cash runway at that time. Investors are cautioned not to place undue reliance on these preliminary and unaudited estimates in the event of material changes.

07:09 EST Corvus Gold, AngloGold Ashanti complete acquisition - AngloGold Ashanti (AU) and Corvus Gold Inc. (KOR) are pleased to announce the successful completion of the previously announced plan of arrangement under the Business Corporations Act between Corvus, 1323606 B.C. Unlimited Liability Company and AngloGold Ashanti Holdings. The Purchaser is an indirect wholly owned subsidiary of AngloGold Ashanti and the Guarantor is a direct wholly owned subsidiary of AngloGold Ashanti. Pursuant to the arrangement agreement, dated as of September 13, 2021, by and among Corvus, the Purchaser and the Guarantor, the Purchaser, among other things, acquired the remaining 80.5% of the outstanding common shares of Corvus not already owned by AngloGold Ashanti and its affiliates. As previously announced, the Arrangement was overwhelmingly approved by Corvus shareholders and optionholders at a special meeting held on January 6, 2022. On January 11, 2022, the Company obtained the final order from the Supreme Court of British Columbia approving the Arrangement. Under the terms of the Arrangement, shareholders of Corvus will receive C$4.10 in cash per Corvus Share. As previously announced, AngloGold Ashanti intends to cause the amalgamated entity to delist its shares from the Toronto Stock Exchange and has submitted applications to the relevant securities regulatory authorities in Canada to cease to be a reporting issuer. In connection with the closing of the Arrangement, in coordination with the Nasdaq Capital Market , a Form 25 relating to the delisting of the amalgamated entity's shares will be filed with the U.S. Securities and Exchange Commission on January 18, 2022 and trading in the amalgamated entity's shares will be suspended on the NASDAQ on January 18, 2022. The amalgamated entity expects the delisting of its shares to become effective 10 days following the filing, or January 28, 2022. The anticipated effective date may be delayed if the SEC postpones the effectiveness of the application to delist for other reasons. Concurrent with the delisting from Nasdaq, the amalgamated entity intends to file a Form 15 with the SEC to terminate the registration of its shares under the U.S. Securities Exchange Act of 1934, as amended and to suspend its reporting obligations with the SEC under the Exchange Act. The amalgamated entity expects that its obligation to file reports with the SEC will be suspended immediately upon the filing of the Form 15. The amalgamated entity reserves the right to delay the filing of the Form 25 or Form 15 or withdraw either form for any reason prior to its effectiveness.

07:07 EST XPO Logistics announces expansion LTL network with new terminals, shops - XPO Logistics announced the opening of two less-than-truckload, LTL, terminals to increase customer service capacity in its North American network. In addition, the company increased production capacity at its trailer manufacturing facility, and will open four more fleet maintenance shops this quarter. In the current quarter, XPO's LTL investments include: 26 new doors at a cross-dock terminal in Sheboygan, Wisconsin; 24 new doors at a cross-dock terminal in Texarkana, Arkansas; New fleet maintenance shops at terminals in Ohio, Florida, New York and Nevada; and Equipment upgrades to the company's LTL trailer manufacturing facility in Searcy, Arkansas, with the expectation of nearly doubling the year-over-year number of units produced in 2022. North American LTL Strategic Actions: Expand its North American LTL door count by 900 doors, or approximately 6%, by year-end 2023; Further improve network flow with targeted initiatives; Continue to implement accessorial charges for detained trailers, oversized freight and special handling; Expand the 2022 graduate count at its US driver training schools, approximately doubling the 2021 count; and Significantly increase the number of units produced at its trailer manufacturing facility.

07:07 EST TransAlta sees 2022 comparable EBITDA C$1.07B-C$1.19B - Sees 2022 comparable EBITDA range $1.065B-$1.185B, Free Cash Flow range $455M-$555M or FCF per share range of $1.68 to $2.05, sustaining capital range of $150M-$170M. "We are pleased to announce that our annual outlook highlights continuing strong cash flow expectations for 2022. Our fleet remains well positioned to capture the ongoing strength we see in the Alberta merchant market. We also remain focused on growth that creates value for our shareholders as we work to deliver on our 2 GW renewables growth target by 2025. In 2021, our team secured 600 MW of new renewables projects demonstrating our competitiveness and capability to deliver our growth strategy across all our geographies," said CEO John Kousinioris. "2022 marks our transition off coal in Canada. With the completion of all our coal-to-gas conversions, and with our renewables growth plan well underway, we have adopted a more ambitious target of 75 per cent emissions reduction over 2015 levels by 2026. We are also proud to be the first publicly-traded electricity company in Canada to commit to setting a science-based emissions reduction target. We are excited for another great year of execution and ESG performance for TransAlta."

07:06 EST Else Nutrition establishes manufacturing capacity in Oregon - ELSE NUTRITION HOLDINGS announced that is has signed an agreement to establish a specialized manufacturing site to process and prepare Else's proprietary specialized, demineralized buckwheat for its infant formula. The Company completed the development of its unique production process for the demineralized buckwheat and anticipates producing the first batch of specially processed buckwheat in Q1 2022. The new facility output will support the infant formula production expected during the first years. The buckwheat will be processed under the strictest quality controls and standards without the use of chemicals or solvents. Else's proprietary process uses all natural processes and maintains the natural chemical composition of the ingredient intact.

07:04 EST ADMA Biologics receives FDA approval for fourth plasma collection center - ADMA Biologics announced that it has received U.S. Food and Drug Administration, FDA, approval for its fourth ADMA BioCenters plasma collection facility located in Goose Creek, South Carolina. In conjunction, the facility was issued a compliance certification from the International Quality Plasma Program, IQPP, confirming the center meets facility and donor criteria for IQPP Certification. This plasma collection facility commenced operations and initiated source plasma collection in the second quarter of 2021. With today's approval, this facility is now FDA-licensed to collect and introduce into interstate commerce, human source plasma for further manufacturing in the U.S. "ADMA is off to an excellent start to 2022 across its business segments, and the approval of the Goose Creek plasma collection center represents another regulatory milestone achievement as well as an important step in ADMA's ambitions to further secure raw material plasma supply," said Adam Grossman, President and Chief Executive Officer of ADMA.

07:03 EST Casi Pharmaceuticals: CNCT19 granted FDA Orphan Drug Designation - CASI Pharmaceuticals announced that the U.S. FDA has granted Orphan Drug Designation to its partner Juventas Cell Therapy Ltd, for CNCT19, an investigational CD-19 directed CAR-T therapy, for the treatment of patients with Acute Lymphoblastic Leukemia.

06:59 EST Sonic Automotive acquires Sun Chevrolet in Chittenango, NY - Sonic Automotive acquired Sun Chevrolet in Chittenango, New York. The dealership was founded by Joe Caputo in 1979, serving residents of Central New York with new and pre-owned vehicles through Sun Chevrolet and three Used Car King pre-owned dealership locations that were acquired by Sonic in December 2020.

06:54 EST NRx Pharmaceuticals expands Access and Right to Try programs for zyesami - NRx Pharmaceuticals announced enhancements to its Expanded Access and Right to Try programs. The programs enable patients with respiratory failure from COVID-19, who have tried all approved medicines, including remdesivir, and who are not able to participate in a clinical study, to receive zyesami upon a physician's prescription. Expanded production of zyesami will also support the ongoing ACTIV-3b trial conducted by the National Institutes of Health both in the US and Brazil. Zyesami is a peptide previously shown to be associated with a two-fold increased odds of survival at 60 days. The subgroup of patients who were treated with zyesami after remdesivir and other approved therapies demonstrated a 2.8-fold increased odds of recovering from respiratory failure by day 28, which was sustained to day 60, together with a four-fold increased odds of surviving to day 60. Adverse events included principally diarrhea and hypotension of patients. The NIH is currently studying zyesami as part of its ACTIV-3b trial, which has enrolled approximately two-thirds of patients and has not identified unexpected safety concerns.

06:52 EST Toyota expects to miss 2022 output goal due to parts shortage - Toyota said in a statement on Tuesday: "At Toyota, we have made repeated adjustments to our production plans due to a parts shortage resulting from the spread of COVID-19, causing various inconveniences to our customers and all parties concerned... Our global production plan in February 2022 is expected to be around 700,000 units. Current demand is very strong, therefore we were aiming for a high February production plan. However, due to the impact of the continuing demand for semiconductors across all industries, we have adjusted our production plan by around 150,000 units globally. As a result of the revision, the full-year production forecast for the fiscal year ending March 31, 2022 is expected to be lower than the previous forecast of 9 million units. With regards to the shortage of semiconductor-related parts, we will continue to examine the situation and consult with all companies involved in considering the use of substitutes where possible in anticipation of a continuing shortage. We will also continue to work with our suppliers in strengthening the supply chain and make every effort to deliver vehicles to our customers as soon as possible."

06:48 EST International Game completes Nevada regulatory approval for Resort Wallet - International Game announced that it completed the final stages of Nevada regulatory approval for its Resort Wallet module of the IGT Advantage casino management system. With this achievement, IGT's entire cashless gaming solution, which includes the option for one-step external funding via IGTPay on personal mobile devices, is approved for deployment throughout the State.

06:46 EST Merck, Ridgeback announce supply agreement with UNICEF for molnupiravir - Merck and Ridgeback Biotherapeutics announced the signing of a long-term supply agreement with the United Nations Children's Fund to facilitate broad global access for molnupiravir, an investigational oral antiviral COVID-19 medicine. Under the agreement, Merck will allocate up to 3M courses of molnupiravir to UNICEF throughout the first half of 2022 for distribution in more than 100 low- and middle-income countries following regulatory authorizations. Merck is developing molnupiravir in collaboration with Ridgeback Biotherapeutics and it has been authorized for use in more than 10 countries, including in the United States, United Kingdom, Japan and Taiwan.

06:39 EST Lantern Pharma announces collaboration, research agreement with DCRC - Lantern Pharma announced a collaboration and research agreement with The Danish Cancer Society Research Center, or DCRC, to support clinical development of Lantern's acylfulvene class drug candidates, LP-100 and LP-184, as well as the development of improved diagnostic methods to identify nucleotide excision repair, or NER, deficient tumors. LP-100 and LP-184 have both shown synthetically lethal impact in tumors that are lacking NER capabilities. The DCRC is a cancer research institute within the Danish Cancer Society. The Danish Cancer Society is Denmark's largest non-government organization and dedicates more than 60% of its budget to research, with the remainder shared between prevention and patient support initiatives. Lantern expects the data, genomic signatures and biological models generated from this collaboration to add millions of data points to RADR and help accelerate the development of new indications for LP-100 and LP-184.

06:33 EST Eldorado Gold sees 2022 gold production 460,000-490,000 ounces - Eldorado Gold provided detailed 2022 production guidance. Highlights: 2022 gold production is expected to be between 460,000-490,000 ounces. Mid-point of 2022 gold production is 30,000 ounces or 7% higher compared to the previous 2022 guidance provided in January 2021, due primarily to increased mining rates at Lamaque, increased recovery rates at Kisladag, and increased throughput and higher grades at Olympias. Mid-point of annual gold production has increased on average by approximately 4% or 21,250 ounces per year for 2022 to 2025, compared to guidance provided in January 2021 for the same period. Quarter-to-quarter gold production in 2022 is expected to fluctuate during the year, with lower production expected in the first quarter at Kisladag from construction and ramp-up of the new high-pressure grinding rolls circuit and lower grades expected at Lamaque during the second and third quarters.

06:13 EST Rayonier Advanced Materials investing in second generation bioethanol plant - Rayonier Advanced Materials is introducing a second generation bioethanol product for Europe's biofuels market. Produced using wood-based feedstock, not in competition with food, RYAM will be among the first in France to produce 2G bioethanol fuel from wood. With a 90% smaller carbon footprint compared to fossil fuel-based gasoline, RYAM's bioethanol product will aim to help petrochemical companies meet their need for clean and renewable energy in the European market and contribute to reduced climate change. Rayonier Advanced Materials' biorefinery model captures residual sugars from its existing pulp process and converts the sugars into 2G bioethanol. Designed to produce up to 21 million liters of bioethanol, construction on RYAM's 2G production facility is scheduled to begin in the spring of 2022 with commercial sales targeted for the summer of 2023. RYAM has entered into a long-term off-take sales agreement with a large international petrochemicals company to purchase the 2G bioethanol and expects to finance a significant portion of its investment with low-cost green loans.

06:09 EST TransUnion Canada launches TruValidate Identity Exchange - TransUnion Canada unveiled the launch of its TruValidate Identity Exchange solution, which builds trust between businesses and consumers by delivering the ability to assess identity risk against a broad set of data to help guard against fraudulent interactions, improve customer experiences and enable profitable growth. Identity Exchange leverages a newly created fraud-specific score and attributes that provide predictive real-time analytics driven by sophisticated, multi-level ensemble modeling. By mining a diverse set of data assets, including trended credit bureau data, fraud flags, as well as application and consortium fraud data, Identity Exchange produces one score that reflects a consumer's level of identity fraud risk. This enables fraud capture among segments of consumers that are often challenging for traditional fraud mitigation products, such as new-to-credit or new-to-country consumers.

06:06 EST Genius Sports secures major expansion of long-term partnership with bet365 - Genius Sports has secured a major expansion of its long-term partnership with bet365. As one of the first sportsbooks to implement Genius Sports' live streaming service, bet365 has now agreed to a major uplift in the company's premium video content including low latency broadcasts from several top tier global soccer competitions and the NFL to bet365 customers outside the U.S. Genius Sports' expanded streaming solution will deliver unique new content to help enhance bet placement and customer retention for bet365. All streaming content will be combined with Genius Sports' leading portfolio of official data across thousands of events per year, including UK football and the NFL. This includes access to the fastest, most accurate data on the English Premier League as well as the NFL's real-time statistics through its proprietary Next Gen Stats. To further enhance bet365's marketing and player engagement strategy, Genius Sports will deliver its official data-driven marketing campaigns, driving deeper engagement and lower cost of acquisition across display, video and connected TV.

06:03 EST Mercantile Bank increases quarterly cash dividend over 3% to 31c per share - Mercantile Bank announced that its board of directors declared a regular quarterly cash dividend of 31c per common share, payable on March 16 to holders of record as of March 4. The 31c cash dividend represents an increase of over 3% from the 30c regular cash dividend paid during Q4.

06:02 EST KBR awarded engineering services contract for project in Oklahoma - KBR announced it has been awarded an engineering services contract by Woodside Energy for its proposed H2OK liquid hydrogen production facility project in Ardmore, Oklahoma. Under the terms of the contract, KBR will provide a front-end engineering design for Woodside's H2OK liquid hydrogen facility. Cryogenic liquid hydrogen is used in the transportation industry as a fuel for fleets where the combustion of liquid hydrogen produces zero-emissions, with water as the only by-product.

05:41 EST Sonida Senior Living announces December occupancy - Sonida Senior Living announced its December 2021 occupancy. December average occupancy increased 40 bps sequentially in a typically slow seasonal period, from November 2021 to 81.6%, its highest point in 2021. Year-over-year average monthly occupancy increased 500 bps compared to 76.6% in December of 2020. For Q4, average occupancy increased sequentially 31.25 bps to 81.3% as compared to the third quarter. Year-over-year quarterly average occupancy grew 392 bps compared to the fourth quarter 2020. "We are pleased with the Company's continued occupancy growth and solid finish to 2021," said Kimberly Lody, president and CEO. "We remain diligent in our activities to keep residents and employees safe from COVID-19 while staying laser focused on continuous and sustainable improvement in the fundamentals of the business."

05:33 EST Molecular Partners, Novartis enter ensovibep license agreement - Molecular Partners (MOLN) announced that Molecular Partners and Novartis (NVS) have entered into a license agreement under which Novartis will in-license global rights to ensovibep from Molecular Partners. Ensovibep is a DARPin antiviral therapeutic candidate to treat COVID-19, which recently reported positive topline data from the Phase 2 EMPATHY clinical study. The finalization of this agreement triggers a milestone payment of CHF 150M to Molecular Partners. Under the license agreement, Molecular Partners will be eligible to receive a 22% royalty on sales in commercial countries, having agreed to forgo royalties in lower income countries and is aligned with Novartis' plans to ensure affordability based on countries' needs and capabilities.

05:29 EST Kosmos completes drilling of Winterfell-2 appraisal well - Kosmos announced completion of the drilling of the Winterfell-2 appraisal well on Block 943 in the Green Canyon area of the U.S. Gulf of Mexico. The Winterfell-2 well was drilled to evaluate the adjacent fault block to the northwest of the original Winterfell discovery and was designed to test two horizons that were oil bearing in the Winterfell-1 well, with an exploration tail into a deeper horizon. The well discovered approximately 40 meters of net oil pay in the first and second horizons with better oil saturation and porosity than pre-drill expectations. The exploration tail has discovered an additional oil-bearing horizon in a deeper reservoir which is also prospective in the blocks immediately to the north. The results of this appraisal well further define the resource potential in the central Winterfell area, with the current estimate around 100M barrels gross. Separately, Kosmos has farmed down an interest in the two blocks immediately to the north of the Winterfell discovery to the owners of the central Winterfell discovery in exchange for cash consideration and the retention of an overriding royalty interest. Kosmos will retain a 35% working interest in the two blocks, which have been significantly de-risked following the results of the Winterfell-1 and Winterfell-2 wells. The Winterfell complex is located within tie back distance to several existing and planned host facilities and the partnership is working to define the development plan.

05:24 EST Onion Global surpasses RMB 100M in GMV during 2022 shopping festival - Onion Global announced that it reached RMB 100M in GMV during its 2022 New Year's Shopping Festival. The New Year promotion ran under the theme of "New Year, New Shopping" and was designed to specifically cater to the consumption needs for the upcoming Spring Festival. The thirteen-day, one-stop, online promotion started its pre-sale on December 24, 2021, and officially ran between December 29, 2021, and January 6. During the period, the company offered consumers a wide range of products. Additionally, the total number of orders exceeded 300,000 and more than 7M views on O'Mall within the first 24 hours after the festival officially started on December 29, 2021.

05:18 EST ADC Therapeutics enters exclusive Zynlonta license agreement with MTPC - ADC Therapeutics announced it has entered an exclusive license agreement with Mitsubishi Tanabe Pharma, or MTPC, for the development and commercialization of Zynlonta for all hematologic and solid tumor indications in Japan. Under the terms of the agreement, ADC Therapeutics will receive an upfront payment of $30M and up to an additional $205M in milestones if certain development and commercial events are achieved. ADC Therapeutics will also receive royalties ranging in percentage from the high teens to the low twenties based on net sales of the product in Japan. MTPC will conduct clinical studies of Zynlonta in Japan and will have the right to participate in any global clinical studies of the product by bearing a portion of the costs of the study.

05:11 EST Fortuna Silver produces 1.98M ounces of silver, 76,162 ounces of gold in Q4